PMC:7195088 / 15642-20795
Annnotations
LitCovid-PubTator
{"project":"LitCovid-PubTator","denotations":[{"id":"655","span":{"begin":62,"end":70},"obj":"Species"},{"id":"656","span":{"begin":252,"end":260},"obj":"Species"},{"id":"657","span":{"begin":596,"end":604},"obj":"Species"},{"id":"658","span":{"begin":841,"end":849},"obj":"Species"},{"id":"659","span":{"begin":1090,"end":1098},"obj":"Species"},{"id":"660","span":{"begin":1795,"end":1803},"obj":"Species"},{"id":"661","span":{"begin":2221,"end":2229},"obj":"Species"},{"id":"662","span":{"begin":2503,"end":2511},"obj":"Species"},{"id":"663","span":{"begin":2795,"end":2803},"obj":"Species"},{"id":"664","span":{"begin":3111,"end":3119},"obj":"Species"},{"id":"665","span":{"begin":3379,"end":3387},"obj":"Species"},{"id":"666","span":{"begin":3688,"end":3696},"obj":"Species"},{"id":"667","span":{"begin":4114,"end":4122},"obj":"Species"},{"id":"668","span":{"begin":4479,"end":4487},"obj":"Species"},{"id":"669","span":{"begin":4720,"end":4728},"obj":"Species"},{"id":"670","span":{"begin":4993,"end":5001},"obj":"Species"},{"id":"671","span":{"begin":5104,"end":5114},"obj":"Species"},{"id":"735","span":{"begin":16,"end":35},"obj":"Chemical"},{"id":"736","span":{"begin":40,"end":58},"obj":"Chemical"},{"id":"737","span":{"begin":209,"end":214},"obj":"Chemical"},{"id":"738","span":{"begin":215,"end":224},"obj":"Chemical"},{"id":"739","span":{"begin":229,"end":248},"obj":"Chemical"},{"id":"740","span":{"begin":425,"end":431},"obj":"Chemical"},{"id":"741","span":{"begin":454,"end":458},"obj":"Chemical"},{"id":"742","span":{"begin":533,"end":552},"obj":"Chemical"},{"id":"743","span":{"begin":557,"end":576},"obj":"Chemical"},{"id":"744","span":{"begin":582,"end":592},"obj":"Chemical"},{"id":"745","span":{"begin":755,"end":774},"obj":"Chemical"},{"id":"746","span":{"begin":779,"end":798},"obj":"Chemical"},{"id":"747","span":{"begin":804,"end":813},"obj":"Chemical"},{"id":"748","span":{"begin":1036,"end":1055},"obj":"Chemical"},{"id":"749","span":{"begin":1060,"end":1071},"obj":"Chemical"},{"id":"750","span":{"begin":1076,"end":1086},"obj":"Chemical"},{"id":"751","span":{"begin":1490,"end":1509},"obj":"Chemical"},{"id":"752","span":{"begin":1728,"end":1738},"obj":"Chemical"},{"id":"753","span":{"begin":1743,"end":1762},"obj":"Chemical"},{"id":"754","span":{"begin":1766,"end":1776},"obj":"Chemical"},{"id":"755","span":{"begin":1780,"end":1791},"obj":"Chemical"},{"id":"756","span":{"begin":2078,"end":2097},"obj":"Chemical"},{"id":"757","span":{"begin":2102,"end":2121},"obj":"Chemical"},{"id":"758","span":{"begin":2373,"end":2392},"obj":"Chemical"},{"id":"759","span":{"begin":2426,"end":2445},"obj":"Chemical"},{"id":"760","span":{"begin":2480,"end":2489},"obj":"Chemical"},{"id":"761","span":{"begin":2655,"end":2674},"obj":"Chemical"},{"id":"762","span":{"begin":2708,"end":2727},"obj":"Chemical"},{"id":"763","span":{"begin":2955,"end":2974},"obj":"Chemical"},{"id":"764","span":{"begin":2980,"end":2998},"obj":"Chemical"},{"id":"765","span":{"begin":3003,"end":3022},"obj":"Chemical"},{"id":"766","span":{"begin":3028,"end":3046},"obj":"Chemical"},{"id":"767","span":{"begin":3052,"end":3062},"obj":"Chemical"},{"id":"768","span":{"begin":3073,"end":3083},"obj":"Chemical"},{"id":"769","span":{"begin":3089,"end":3099},"obj":"Chemical"},{"id":"770","span":{"begin":3307,"end":3326},"obj":"Chemical"},{"id":"771","span":{"begin":3331,"end":3349},"obj":"Chemical"},{"id":"772","span":{"begin":3354,"end":3362},"obj":"Chemical"},{"id":"773","span":{"begin":3558,"end":3577},"obj":"Chemical"},{"id":"774","span":{"begin":3582,"end":3600},"obj":"Chemical"},{"id":"775","span":{"begin":3605,"end":3624},"obj":"Chemical"},{"id":"776","span":{"begin":3653,"end":3663},"obj":"Chemical"},{"id":"777","span":{"begin":3854,"end":3873},"obj":"Chemical"},{"id":"778","span":{"begin":3877,"end":3887},"obj":"Chemical"},{"id":"779","span":{"begin":3891,"end":3902},"obj":"Chemical"},{"id":"780","span":{"begin":3906,"end":3924},"obj":"Chemical"},{"id":"781","span":{"begin":3928,"end":3939},"obj":"Chemical"},{"id":"782","span":{"begin":3957,"end":3969},"obj":"Chemical"},{"id":"783","span":{"begin":3994,"end":4013},"obj":"Chemical"},{"id":"784","span":{"begin":4017,"end":4027},"obj":"Chemical"},{"id":"785","span":{"begin":4031,"end":4042},"obj":"Chemical"},{"id":"786","span":{"begin":4046,"end":4064},"obj":"Chemical"},{"id":"787","span":{"begin":4068,"end":4079},"obj":"Chemical"},{"id":"788","span":{"begin":4097,"end":4109},"obj":"Chemical"},{"id":"789","span":{"begin":4400,"end":4410},"obj":"Chemical"},{"id":"790","span":{"begin":4428,"end":4447},"obj":"Chemical"},{"id":"791","span":{"begin":4697,"end":4716},"obj":"Chemical"},{"id":"792","span":{"begin":4755,"end":4774},"obj":"Chemical"},{"id":"793","span":{"begin":4854,"end":4873},"obj":"Chemical"},{"id":"908","span":{"begin":81,"end":89},"obj":"Disease"},{"id":"909","span":{"begin":276,"end":284},"obj":"Disease"},{"id":"910","span":{"begin":610,"end":618},"obj":"Disease"},{"id":"911","span":{"begin":855,"end":863},"obj":"Disease"},{"id":"912","span":{"begin":1114,"end":1132},"obj":"Disease"},{"id":"913","span":{"begin":1240,"end":1245},"obj":"Disease"},{"id":"914","span":{"begin":1247,"end":1252},"obj":"Disease"},{"id":"915","span":{"begin":1320,"end":1325},"obj":"Disease"},{"id":"916","span":{"begin":1327,"end":1332},"obj":"Disease"},{"id":"917","span":{"begin":1555,"end":1563},"obj":"Disease"},{"id":"918","span":{"begin":1679,"end":1687},"obj":"Disease"},{"id":"919","span":{"begin":1809,"end":1827},"obj":"Disease"},{"id":"920","span":{"begin":1902,"end":1907},"obj":"Disease"},{"id":"921","span":{"begin":1948,"end":1970},"obj":"Disease"},{"id":"922","span":{"begin":2235,"end":2243},"obj":"Disease"},{"id":"923","span":{"begin":2517,"end":2525},"obj":"Disease"},{"id":"924","span":{"begin":2809,"end":2817},"obj":"Disease"},{"id":"925","span":{"begin":3135,"end":3153},"obj":"Disease"},{"id":"926","span":{"begin":3393,"end":3401},"obj":"Disease"},{"id":"927","span":{"begin":3489,"end":3497},"obj":"Disease"},{"id":"928","span":{"begin":3702,"end":3710},"obj":"Disease"},{"id":"929","span":{"begin":4128,"end":4136},"obj":"Disease"},{"id":"930","span":{"begin":4255,"end":4260},"obj":"Disease"},{"id":"931","span":{"begin":4330,"end":4347},"obj":"Disease"},{"id":"932","span":{"begin":4512,"end":4520},"obj":"Disease"},{"id":"933","span":{"begin":4600,"end":4609},"obj":"Disease"},{"id":"934","span":{"begin":4739,"end":4747},"obj":"Disease"},{"id":"935","span":{"begin":4946,"end":4977},"obj":"Disease"},{"id":"936","span":{"begin":5026,"end":5034},"obj":"Disease"}],"attributes":[{"id":"A655","pred":"tao:has_database_id","subj":"655","obj":"Tax:9606"},{"id":"A656","pred":"tao:has_database_id","subj":"656","obj":"Tax:9606"},{"id":"A657","pred":"tao:has_database_id","subj":"657","obj":"Tax:9606"},{"id":"A658","pred":"tao:has_database_id","subj":"658","obj":"Tax:9606"},{"id":"A659","pred":"tao:has_database_id","subj":"659","obj":"Tax:9606"},{"id":"A660","pred":"tao:has_database_id","subj":"660","obj":"Tax:9606"},{"id":"A661","pred":"tao:has_database_id","subj":"661","obj":"Tax:9606"},{"id":"A662","pred":"tao:has_database_id","subj":"662","obj":"Tax:9606"},{"id":"A663","pred":"tao:has_database_id","subj":"663","obj":"Tax:9606"},{"id":"A664","pred":"tao:has_database_id","subj":"664","obj":"Tax:9606"},{"id":"A665","pred":"tao:has_database_id","subj":"665","obj":"Tax:9606"},{"id":"A666","pred":"tao:has_database_id","subj":"666","obj":"Tax:9606"},{"id":"A667","pred":"tao:has_database_id","subj":"667","obj":"Tax:9606"},{"id":"A668","pred":"tao:has_database_id","subj":"668","obj":"Tax:9606"},{"id":"A669","pred":"tao:has_database_id","subj":"669","obj":"Tax:9606"},{"id":"A670","pred":"tao:has_database_id","subj":"670","obj":"Tax:9606"},{"id":"A671","pred":"tao:has_database_id","subj":"671","obj":"Tax:2697049"},{"id":"A735","pred":"tao:has_database_id","subj":"735","obj":"MESH:C558899"},{"id":"A736","pred":"tao:has_database_id","subj":"736","obj":"MESH:D006886"},{"id":"A738","pred":"tao:has_database_id","subj":"738","obj":"MESH:D019438"},{"id":"A739","pred":"tao:has_database_id","subj":"739","obj":"MESH:C558899"},{"id":"A740","pred":"tao:has_database_id","subj":"740","obj":"MESH:D010100"},{"id":"A742","pred":"tao:has_database_id","subj":"742","obj":"MESH:C558899"},{"id":"A743","pred":"tao:has_database_id","subj":"743","obj":"MESH:C558899"},{"id":"A744","pred":"tao:has_database_id","subj":"744","obj":"MESH:C086979"},{"id":"A745","pred":"tao:has_database_id","subj":"745","obj":"MESH:C558899"},{"id":"A746","pred":"tao:has_database_id","subj":"746","obj":"MESH:C558899"},{"id":"A747","pred":"tao:has_database_id","subj":"747","obj":"MESH:D012254"},{"id":"A748","pred":"tao:has_database_id","subj":"748","obj":"MESH:C558899"},{"id":"A749","pred":"tao:has_database_id","subj":"749","obj":"MESH:D053139"},{"id":"A750","pred":"tao:has_database_id","subj":"750","obj":"MESH:C086979"},{"id":"A751","pred":"tao:has_database_id","subj":"751","obj":"MESH:C558899"},{"id":"A753","pred":"tao:has_database_id","subj":"753","obj":"MESH:C558899"},{"id":"A754","pred":"tao:has_database_id","subj":"754","obj":"MESH:C086979"},{"id":"A755","pred":"tao:has_database_id","subj":"755","obj":"MESH:D002738"},{"id":"A756","pred":"tao:has_database_id","subj":"756","obj":"MESH:C558899"},{"id":"A757","pred":"tao:has_database_id","subj":"757","obj":"MESH:C558899"},{"id":"A758","pred":"tao:has_database_id","subj":"758","obj":"MESH:C558899"},{"id":"A759","pred":"tao:has_database_id","subj":"759","obj":"MESH:C558899"},{"id":"A761","pred":"tao:has_database_id","subj":"761","obj":"MESH:C558899"},{"id":"A762","pred":"tao:has_database_id","subj":"762","obj":"MESH:C558899"},{"id":"A763","pred":"tao:has_database_id","subj":"763","obj":"MESH:C558899"},{"id":"A764","pred":"tao:has_database_id","subj":"764","obj":"MESH:D006886"},{"id":"A765","pred":"tao:has_database_id","subj":"765","obj":"MESH:C558899"},{"id":"A766","pred":"tao:has_database_id","subj":"766","obj":"MESH:D006886"},{"id":"A767","pred":"tao:has_database_id","subj":"767","obj":"MESH:D007978"},{"id":"A768","pred":"tao:has_database_id","subj":"768","obj":"MESH:D019819"},{"id":"A769","pred":"tao:has_database_id","subj":"769","obj":"MESH:D000068759"},{"id":"A770","pred":"tao:has_database_id","subj":"770","obj":"MESH:C558899"},{"id":"A771","pred":"tao:has_database_id","subj":"771","obj":"MESH:D006886"},{"id":"A772","pred":"tao:has_database_id","subj":"772","obj":"MESH:D019808"},{"id":"A773","pred":"tao:has_database_id","subj":"773","obj":"MESH:C558899"},{"id":"A774","pred":"tao:has_database_id","subj":"774","obj":"MESH:D006886"},{"id":"A775","pred":"tao:has_database_id","subj":"775","obj":"MESH:C558899"},{"id":"A776","pred":"tao:has_database_id","subj":"776","obj":"MESH:C000606551"},{"id":"A777","pred":"tao:has_database_id","subj":"777","obj":"MESH:C558899"},{"id":"A778","pred":"tao:has_database_id","subj":"778","obj":"MESH:C086979"},{"id":"A779","pred":"tao:has_database_id","subj":"779","obj":"MESH:D002738"},{"id":"A780","pred":"tao:has_database_id","subj":"780","obj":"MESH:D006886"},{"id":"A781","pred":"tao:has_database_id","subj":"781","obj":"MESH:D053139"},{"id":"A782","pred":"tao:has_database_id","subj":"782","obj":"MESH:D017963"},{"id":"A783","pred":"tao:has_database_id","subj":"783","obj":"MESH:C558899"},{"id":"A784","pred":"tao:has_database_id","subj":"784","obj":"MESH:C086979"},{"id":"A785","pred":"tao:has_database_id","subj":"785","obj":"MESH:D002738"},{"id":"A786","pred":"tao:has_database_id","subj":"786","obj":"MESH:D006886"},{"id":"A787","pred":"tao:has_database_id","subj":"787","obj":"MESH:D053139"},{"id":"A788","pred":"tao:has_database_id","subj":"788","obj":"MESH:D017963"},{"id":"A789","pred":"tao:has_database_id","subj":"789","obj":"MESH:D003078"},{"id":"A790","pred":"tao:has_database_id","subj":"790","obj":"MESH:C558899"},{"id":"A791","pred":"tao:has_database_id","subj":"791","obj":"MESH:C558899"},{"id":"A792","pred":"tao:has_database_id","subj":"792","obj":"MESH:C558899"},{"id":"A793","pred":"tao:has_database_id","subj":"793","obj":"MESH:C558899"},{"id":"A908","pred":"tao:has_database_id","subj":"908","obj":"MESH:C000657245"},{"id":"A909","pred":"tao:has_database_id","subj":"909","obj":"MESH:C000657245"},{"id":"A910","pred":"tao:has_database_id","subj":"910","obj":"MESH:C000657245"},{"id":"A911","pred":"tao:has_database_id","subj":"911","obj":"MESH:C000657245"},{"id":"A912","pred":"tao:has_database_id","subj":"912","obj":"MESH:C000657245"},{"id":"A913","pred":"tao:has_database_id","subj":"913","obj":"MESH:D005334"},{"id":"A914","pred":"tao:has_database_id","subj":"914","obj":"MESH:D003371"},{"id":"A915","pred":"tao:has_database_id","subj":"915","obj":"MESH:D005334"},{"id":"A916","pred":"tao:has_database_id","subj":"916","obj":"MESH:D003371"},{"id":"A917","pred":"tao:has_database_id","subj":"917","obj":"MESH:C000657245"},{"id":"A918","pred":"tao:has_database_id","subj":"918","obj":"MESH:C000657245"},{"id":"A919","pred":"tao:has_database_id","subj":"919","obj":"MESH:C000657245"},{"id":"A920","pred":"tao:has_database_id","subj":"920","obj":"MESH:D005334"},{"id":"A921","pred":"tao:has_database_id","subj":"921","obj":"MESH:D011014"},{"id":"A922","pred":"tao:has_database_id","subj":"922","obj":"MESH:C000657245"},{"id":"A923","pred":"tao:has_database_id","subj":"923","obj":"MESH:C000657245"},{"id":"A924","pred":"tao:has_database_id","subj":"924","obj":"MESH:C000657245"},{"id":"A925","pred":"tao:has_database_id","subj":"925","obj":"MESH:C000657245"},{"id":"A926","pred":"tao:has_database_id","subj":"926","obj":"MESH:C000657245"},{"id":"A927","pred":"tao:has_database_id","subj":"927","obj":"MESH:C000657245"},{"id":"A928","pred":"tao:has_database_id","subj":"928","obj":"MESH:C000657245"},{"id":"A929","pred":"tao:has_database_id","subj":"929","obj":"MESH:C000657245"},{"id":"A930","pred":"tao:has_database_id","subj":"930","obj":"MESH:D005334"},{"id":"A931","pred":"tao:has_database_id","subj":"931","obj":"MESH:D011014"},{"id":"A932","pred":"tao:has_database_id","subj":"932","obj":"MESH:C000657245"},{"id":"A933","pred":"tao:has_database_id","subj":"933","obj":"MESH:D003643"},{"id":"A934","pred":"tao:has_database_id","subj":"934","obj":"MESH:C000657245"},{"id":"A935","pred":"tao:has_database_id","subj":"935","obj":"MESH:D007625"},{"id":"A936","pred":"tao:has_database_id","subj":"936","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"• Comparison of lopinavir/ritonavir vs. hydroxychloroquine in patients with mild COVID-19. Open-label RCT (NCT04307693, recruiting). Primary endpoint: virus load at day 3, 5, 7, 10, 14 and 18.\n• Comparison of ASC09/ritonavir vs. lopinavir/ritonavir in patients with confirmed COVID-19 pneumoniae. Open-label RCT (NCT04261907, not yet recruiting). Primary endpoint: adverse outcome at day 14 (composite of Spo 2 ≤ 93% without oxygen supplementation, PaO2/FiO2 ≤ 300 mm Hg or respiratory rate ≥ 30 breaths per minute).\n• Comparison of lopinavir/ritonavir vs. lopinavir/ritonavir plus umifenovir in patients with COVID-19. Open-label RCT (NCT04252885, recruiting). Primary endpoint: rate of virus inhibition at day 0, 2, 4, 7, 10, 14 and 21.\n• Comparison of lopinavir/ritonavir vs. lopinavir/ritonavir plus ribavirin plus interferon beta 1b in patients with COVID-19. Open-label RCT (NCT04276688, recruiting). Primary endpoint: time to negative nasopharyngeal swab RT-PCR (follow-up 30 days).\n• Comparison of only supportive treatment vs. lopinavir/ritonavir vs. oseltamivir vs. umifenovir in patients with confirmed COVID-19 pneumonia. Open-label RCT (NCT04255017, recruiting). Primary endpoints: (a) rate of disease remission (mild disease: fever, cough and other symptoms relieved with improved lung CT; severe disease: fever, cough and other symptoms relieved with improved lung CT, Spo 2 \u003e 93% or Pao 2/Fio 2 \u003e 300 mm Hg); (b) time to lung recovery.\n• Comparison of chemoprophylaxis with lopinavir/ritonavir vs. placebo in healthcare workers exposed to COVID-19. Double-blind RCT (NCT04328285, not yet recruiting). Primary endpoint: occurrence of a symptomatic or asymptomatic COVID-19 (follow-up 2.5 months).\n• Comparison of carrimycin vs. lopinavir/ritonavir or umifenovir or chloroquine in patients with COVID-19 pneumonia. Open-label RCT (NCT04286503, not yet recruiting). Primary endpoints: (a) fever to normal time (follow-up 30 days); (b) pulmonary inflammation resolution time (follow-up 30 days); (c) negative conversion of throat swab RT-PCR at EOT.\n• Comparison of lopinavir/ritonavir vs. lopinavir/ritonavir plus xiyanping (injectable component derived from a plant used in traditional Chinese medicine) in patients with COVID-19. Open-label RCT (NCT04295551, not yet recruiting). Primary endpoint: clinical recovery time (follow-up 28 days).\n• Comparison of lopinavir/ritonavir plus inhaled interferon alfa vs. lopinavir/ritonavir plus inhaled interferon alfa plus xiyanping injection in patients with COVID-19. Open-label RCT (NCT04275388, not yet recruiting). Primary endpoint: clinical recovery time (follow-up 14 days).\n• Comparison of lopinavir/ritonavir plus inhaled interferon alfa vs. lopinavir/ritonavir plus inhaled interferon alfa plus traditional Chinese medicines in patients with COVID-19. Open-label RCT (NCT04251871, recruiting). Primary endpoint: time to complete remission of symptoms (follow-up 28 days).\n• Comparison of lopinavir/ritonavir plus hydroxychloroquine vs. lopinavir/ritonavir plus hydroxychloroquine plus levamisole pill plus budesonide plus formoterol inhaler in patients with nonsevere COVID-19 pneumonia. Partly blinded RCT (NCT04331470, not yet recruiting). Primary endpoint: (a) clear CT scan at 3–7 days; (b) negative RT-PCR at 3–7 days.\n• Comparison of lopinavir/ritonavir vs. hydroxychloroquine vs. losartan vs. placebos in patients with COVID-19. Double-blind, adaptive RCT (NCT04328012, not yet recruiting). Primary endpoint: NIAID COVID-19 ordinal severity scale (follow-up 60 days).\n• Comparison of lopinavir/ritonavir vs. hydroxychloroquine vs. lopinavir/ritonavir plus interferon beta 1a vs. remdesivir vs. standard of care in patients with COVID-19. Double-blind, adaptive RCT (NCT04315948, recruiting). Primary endpoint: severity rating on a 7-point ordinal scale at day 15.\n• Comparison of lopinavir/ritonavir or umifenovir or chloroquine or hydroxychloroquine or oseltamivir (with or without azithromycin) vs. natural honey plus lopinavir/ritonavir or umifenovir or chloroquine or hydroxychloroquine or oseltamivir (with or without azithromycin) in patients with COVID-19. Single-blind RCT (NCT04323345, not yet recruiting). Primary endpoints: (a) positive to negative swabs at day 14; (b) fever to normal temperature in days (follow-up 14 days); (c) resolution of lung inflammation in CT or X-ray (follow-up 30 days).\n• Comparison of colchicine (with or without lopinavir/ritonavir) vs. local standard of care in patients with moderate to severe COVID-19. Open-label RCT (NCT04328480, not yet recruiting). Primary endpoint: all-cause mortality (follow-up 30 days).\n• Comparison of oseltamivir plus chloroquine vs. oseltamivir plus lopinavir/ritonavir in patients with mild COVID-19 and of lopinavir/ritonavir plus oseltamivir vs. darunavir/ritonavir plus oseltamivir vs. favipiravir plus lopinavir/ritonavir vs. darunavir/ritonavir plus oseltamivir plus chloroquine vs. darunavir/ritonavir plus favipiravir plus oseltamivir in patients with moderate to severe COVID-19. Open-label RCT (NCT04303299, not yet recruiting). Primary endpoint: SARS-CoV-2 eradication time (follow-up 24 weeks)."}
LitCovid-PD-FMA-UBERON
{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T8","span":{"begin":1295,"end":1299},"obj":"Body_part"},{"id":"T9","span":{"begin":1375,"end":1379},"obj":"Body_part"},{"id":"T10","span":{"begin":1437,"end":1441},"obj":"Body_part"},{"id":"T11","span":{"begin":2035,"end":2041},"obj":"Body_part"},{"id":"T12","span":{"begin":4330,"end":4334},"obj":"Body_part"}],"attributes":[{"id":"A8","pred":"fma_id","subj":"T8","obj":"http://purl.org/sig/ont/fma/fma7195"},{"id":"A9","pred":"fma_id","subj":"T9","obj":"http://purl.org/sig/ont/fma/fma7195"},{"id":"A10","pred":"fma_id","subj":"T10","obj":"http://purl.org/sig/ont/fma/fma7195"},{"id":"A11","pred":"fma_id","subj":"T11","obj":"http://purl.org/sig/ont/fma/fma228738"},{"id":"A12","pred":"fma_id","subj":"T12","obj":"http://purl.org/sig/ont/fma/fma7195"}],"text":"• Comparison of lopinavir/ritonavir vs. hydroxychloroquine in patients with mild COVID-19. Open-label RCT (NCT04307693, recruiting). Primary endpoint: virus load at day 3, 5, 7, 10, 14 and 18.\n• Comparison of ASC09/ritonavir vs. lopinavir/ritonavir in patients with confirmed COVID-19 pneumoniae. Open-label RCT (NCT04261907, not yet recruiting). Primary endpoint: adverse outcome at day 14 (composite of Spo 2 ≤ 93% without oxygen supplementation, PaO2/FiO2 ≤ 300 mm Hg or respiratory rate ≥ 30 breaths per minute).\n• Comparison of lopinavir/ritonavir vs. lopinavir/ritonavir plus umifenovir in patients with COVID-19. Open-label RCT (NCT04252885, recruiting). Primary endpoint: rate of virus inhibition at day 0, 2, 4, 7, 10, 14 and 21.\n• Comparison of lopinavir/ritonavir vs. lopinavir/ritonavir plus ribavirin plus interferon beta 1b in patients with COVID-19. Open-label RCT (NCT04276688, recruiting). Primary endpoint: time to negative nasopharyngeal swab RT-PCR (follow-up 30 days).\n• Comparison of only supportive treatment vs. lopinavir/ritonavir vs. oseltamivir vs. umifenovir in patients with confirmed COVID-19 pneumonia. Open-label RCT (NCT04255017, recruiting). Primary endpoints: (a) rate of disease remission (mild disease: fever, cough and other symptoms relieved with improved lung CT; severe disease: fever, cough and other symptoms relieved with improved lung CT, Spo 2 \u003e 93% or Pao 2/Fio 2 \u003e 300 mm Hg); (b) time to lung recovery.\n• Comparison of chemoprophylaxis with lopinavir/ritonavir vs. placebo in healthcare workers exposed to COVID-19. Double-blind RCT (NCT04328285, not yet recruiting). Primary endpoint: occurrence of a symptomatic or asymptomatic COVID-19 (follow-up 2.5 months).\n• Comparison of carrimycin vs. lopinavir/ritonavir or umifenovir or chloroquine in patients with COVID-19 pneumonia. Open-label RCT (NCT04286503, not yet recruiting). Primary endpoints: (a) fever to normal time (follow-up 30 days); (b) pulmonary inflammation resolution time (follow-up 30 days); (c) negative conversion of throat swab RT-PCR at EOT.\n• Comparison of lopinavir/ritonavir vs. lopinavir/ritonavir plus xiyanping (injectable component derived from a plant used in traditional Chinese medicine) in patients with COVID-19. Open-label RCT (NCT04295551, not yet recruiting). Primary endpoint: clinical recovery time (follow-up 28 days).\n• Comparison of lopinavir/ritonavir plus inhaled interferon alfa vs. lopinavir/ritonavir plus inhaled interferon alfa plus xiyanping injection in patients with COVID-19. Open-label RCT (NCT04275388, not yet recruiting). Primary endpoint: clinical recovery time (follow-up 14 days).\n• Comparison of lopinavir/ritonavir plus inhaled interferon alfa vs. lopinavir/ritonavir plus inhaled interferon alfa plus traditional Chinese medicines in patients with COVID-19. Open-label RCT (NCT04251871, recruiting). Primary endpoint: time to complete remission of symptoms (follow-up 28 days).\n• Comparison of lopinavir/ritonavir plus hydroxychloroquine vs. lopinavir/ritonavir plus hydroxychloroquine plus levamisole pill plus budesonide plus formoterol inhaler in patients with nonsevere COVID-19 pneumonia. Partly blinded RCT (NCT04331470, not yet recruiting). Primary endpoint: (a) clear CT scan at 3–7 days; (b) negative RT-PCR at 3–7 days.\n• Comparison of lopinavir/ritonavir vs. hydroxychloroquine vs. losartan vs. placebos in patients with COVID-19. Double-blind, adaptive RCT (NCT04328012, not yet recruiting). Primary endpoint: NIAID COVID-19 ordinal severity scale (follow-up 60 days).\n• Comparison of lopinavir/ritonavir vs. hydroxychloroquine vs. lopinavir/ritonavir plus interferon beta 1a vs. remdesivir vs. standard of care in patients with COVID-19. Double-blind, adaptive RCT (NCT04315948, recruiting). Primary endpoint: severity rating on a 7-point ordinal scale at day 15.\n• Comparison of lopinavir/ritonavir or umifenovir or chloroquine or hydroxychloroquine or oseltamivir (with or without azithromycin) vs. natural honey plus lopinavir/ritonavir or umifenovir or chloroquine or hydroxychloroquine or oseltamivir (with or without azithromycin) in patients with COVID-19. Single-blind RCT (NCT04323345, not yet recruiting). Primary endpoints: (a) positive to negative swabs at day 14; (b) fever to normal temperature in days (follow-up 14 days); (c) resolution of lung inflammation in CT or X-ray (follow-up 30 days).\n• Comparison of colchicine (with or without lopinavir/ritonavir) vs. local standard of care in patients with moderate to severe COVID-19. Open-label RCT (NCT04328480, not yet recruiting). Primary endpoint: all-cause mortality (follow-up 30 days).\n• Comparison of oseltamivir plus chloroquine vs. oseltamivir plus lopinavir/ritonavir in patients with mild COVID-19 and of lopinavir/ritonavir plus oseltamivir vs. darunavir/ritonavir plus oseltamivir vs. favipiravir plus lopinavir/ritonavir vs. darunavir/ritonavir plus oseltamivir plus chloroquine vs. darunavir/ritonavir plus favipiravir plus oseltamivir in patients with moderate to severe COVID-19. Open-label RCT (NCT04303299, not yet recruiting). Primary endpoint: SARS-CoV-2 eradication time (follow-up 24 weeks)."}
LitCovid-PD-UBERON
{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T5","span":{"begin":1295,"end":1299},"obj":"Body_part"},{"id":"T6","span":{"begin":1375,"end":1379},"obj":"Body_part"},{"id":"T7","span":{"begin":1437,"end":1441},"obj":"Body_part"},{"id":"T8","span":{"begin":2035,"end":2041},"obj":"Body_part"},{"id":"T9","span":{"begin":3515,"end":3520},"obj":"Body_part"},{"id":"T10","span":{"begin":3821,"end":3826},"obj":"Body_part"},{"id":"T11","span":{"begin":4330,"end":4334},"obj":"Body_part"}],"attributes":[{"id":"A5","pred":"uberon_id","subj":"T5","obj":"http://purl.obolibrary.org/obo/UBERON_0002048"},{"id":"A6","pred":"uberon_id","subj":"T6","obj":"http://purl.obolibrary.org/obo/UBERON_0002048"},{"id":"A7","pred":"uberon_id","subj":"T7","obj":"http://purl.obolibrary.org/obo/UBERON_0002048"},{"id":"A8","pred":"uberon_id","subj":"T8","obj":"http://purl.obolibrary.org/obo/UBERON_0000341"},{"id":"A9","pred":"uberon_id","subj":"T9","obj":"http://purl.obolibrary.org/obo/UBERON_0002542"},{"id":"A10","pred":"uberon_id","subj":"T10","obj":"http://purl.obolibrary.org/obo/UBERON_0002542"},{"id":"A11","pred":"uberon_id","subj":"T11","obj":"http://purl.obolibrary.org/obo/UBERON_0002048"}],"text":"• Comparison of lopinavir/ritonavir vs. hydroxychloroquine in patients with mild COVID-19. Open-label RCT (NCT04307693, recruiting). Primary endpoint: virus load at day 3, 5, 7, 10, 14 and 18.\n• Comparison of ASC09/ritonavir vs. lopinavir/ritonavir in patients with confirmed COVID-19 pneumoniae. Open-label RCT (NCT04261907, not yet recruiting). Primary endpoint: adverse outcome at day 14 (composite of Spo 2 ≤ 93% without oxygen supplementation, PaO2/FiO2 ≤ 300 mm Hg or respiratory rate ≥ 30 breaths per minute).\n• Comparison of lopinavir/ritonavir vs. lopinavir/ritonavir plus umifenovir in patients with COVID-19. Open-label RCT (NCT04252885, recruiting). Primary endpoint: rate of virus inhibition at day 0, 2, 4, 7, 10, 14 and 21.\n• Comparison of lopinavir/ritonavir vs. lopinavir/ritonavir plus ribavirin plus interferon beta 1b in patients with COVID-19. Open-label RCT (NCT04276688, recruiting). Primary endpoint: time to negative nasopharyngeal swab RT-PCR (follow-up 30 days).\n• Comparison of only supportive treatment vs. lopinavir/ritonavir vs. oseltamivir vs. umifenovir in patients with confirmed COVID-19 pneumonia. Open-label RCT (NCT04255017, recruiting). Primary endpoints: (a) rate of disease remission (mild disease: fever, cough and other symptoms relieved with improved lung CT; severe disease: fever, cough and other symptoms relieved with improved lung CT, Spo 2 \u003e 93% or Pao 2/Fio 2 \u003e 300 mm Hg); (b) time to lung recovery.\n• Comparison of chemoprophylaxis with lopinavir/ritonavir vs. placebo in healthcare workers exposed to COVID-19. Double-blind RCT (NCT04328285, not yet recruiting). Primary endpoint: occurrence of a symptomatic or asymptomatic COVID-19 (follow-up 2.5 months).\n• Comparison of carrimycin vs. lopinavir/ritonavir or umifenovir or chloroquine in patients with COVID-19 pneumonia. Open-label RCT (NCT04286503, not yet recruiting). Primary endpoints: (a) fever to normal time (follow-up 30 days); (b) pulmonary inflammation resolution time (follow-up 30 days); (c) negative conversion of throat swab RT-PCR at EOT.\n• Comparison of lopinavir/ritonavir vs. lopinavir/ritonavir plus xiyanping (injectable component derived from a plant used in traditional Chinese medicine) in patients with COVID-19. Open-label RCT (NCT04295551, not yet recruiting). Primary endpoint: clinical recovery time (follow-up 28 days).\n• Comparison of lopinavir/ritonavir plus inhaled interferon alfa vs. lopinavir/ritonavir plus inhaled interferon alfa plus xiyanping injection in patients with COVID-19. Open-label RCT (NCT04275388, not yet recruiting). Primary endpoint: clinical recovery time (follow-up 14 days).\n• Comparison of lopinavir/ritonavir plus inhaled interferon alfa vs. lopinavir/ritonavir plus inhaled interferon alfa plus traditional Chinese medicines in patients with COVID-19. Open-label RCT (NCT04251871, recruiting). Primary endpoint: time to complete remission of symptoms (follow-up 28 days).\n• Comparison of lopinavir/ritonavir plus hydroxychloroquine vs. lopinavir/ritonavir plus hydroxychloroquine plus levamisole pill plus budesonide plus formoterol inhaler in patients with nonsevere COVID-19 pneumonia. Partly blinded RCT (NCT04331470, not yet recruiting). Primary endpoint: (a) clear CT scan at 3–7 days; (b) negative RT-PCR at 3–7 days.\n• Comparison of lopinavir/ritonavir vs. hydroxychloroquine vs. losartan vs. placebos in patients with COVID-19. Double-blind, adaptive RCT (NCT04328012, not yet recruiting). Primary endpoint: NIAID COVID-19 ordinal severity scale (follow-up 60 days).\n• Comparison of lopinavir/ritonavir vs. hydroxychloroquine vs. lopinavir/ritonavir plus interferon beta 1a vs. remdesivir vs. standard of care in patients with COVID-19. Double-blind, adaptive RCT (NCT04315948, recruiting). Primary endpoint: severity rating on a 7-point ordinal scale at day 15.\n• Comparison of lopinavir/ritonavir or umifenovir or chloroquine or hydroxychloroquine or oseltamivir (with or without azithromycin) vs. natural honey plus lopinavir/ritonavir or umifenovir or chloroquine or hydroxychloroquine or oseltamivir (with or without azithromycin) in patients with COVID-19. Single-blind RCT (NCT04323345, not yet recruiting). Primary endpoints: (a) positive to negative swabs at day 14; (b) fever to normal temperature in days (follow-up 14 days); (c) resolution of lung inflammation in CT or X-ray (follow-up 30 days).\n• Comparison of colchicine (with or without lopinavir/ritonavir) vs. local standard of care in patients with moderate to severe COVID-19. Open-label RCT (NCT04328480, not yet recruiting). Primary endpoint: all-cause mortality (follow-up 30 days).\n• Comparison of oseltamivir plus chloroquine vs. oseltamivir plus lopinavir/ritonavir in patients with mild COVID-19 and of lopinavir/ritonavir plus oseltamivir vs. darunavir/ritonavir plus oseltamivir vs. favipiravir plus lopinavir/ritonavir vs. darunavir/ritonavir plus oseltamivir plus chloroquine vs. darunavir/ritonavir plus favipiravir plus oseltamivir in patients with moderate to severe COVID-19. Open-label RCT (NCT04303299, not yet recruiting). Primary endpoint: SARS-CoV-2 eradication time (follow-up 24 weeks)."}
LitCovid-PD-HP
{"project":"LitCovid-PD-HP","denotations":[{"id":"T15","span":{"begin":285,"end":295},"obj":"Phenotype"},{"id":"T16","span":{"begin":1123,"end":1132},"obj":"Phenotype"},{"id":"T17","span":{"begin":1240,"end":1245},"obj":"Phenotype"},{"id":"T18","span":{"begin":1247,"end":1252},"obj":"Phenotype"},{"id":"T19","span":{"begin":1320,"end":1325},"obj":"Phenotype"},{"id":"T20","span":{"begin":1327,"end":1332},"obj":"Phenotype"},{"id":"T21","span":{"begin":1818,"end":1827},"obj":"Phenotype"},{"id":"T22","span":{"begin":1902,"end":1907},"obj":"Phenotype"},{"id":"T23","span":{"begin":3144,"end":3153},"obj":"Phenotype"},{"id":"T24","span":{"begin":4255,"end":4260},"obj":"Phenotype"}],"attributes":[{"id":"A15","pred":"hp_id","subj":"T15","obj":"http://purl.obolibrary.org/obo/HP_0002090"},{"id":"A16","pred":"hp_id","subj":"T16","obj":"http://purl.obolibrary.org/obo/HP_0002090"},{"id":"A17","pred":"hp_id","subj":"T17","obj":"http://purl.obolibrary.org/obo/HP_0001945"},{"id":"A18","pred":"hp_id","subj":"T18","obj":"http://purl.obolibrary.org/obo/HP_0012735"},{"id":"A19","pred":"hp_id","subj":"T19","obj":"http://purl.obolibrary.org/obo/HP_0001945"},{"id":"A20","pred":"hp_id","subj":"T20","obj":"http://purl.obolibrary.org/obo/HP_0012735"},{"id":"A21","pred":"hp_id","subj":"T21","obj":"http://purl.obolibrary.org/obo/HP_0002090"},{"id":"A22","pred":"hp_id","subj":"T22","obj":"http://purl.obolibrary.org/obo/HP_0001945"},{"id":"A23","pred":"hp_id","subj":"T23","obj":"http://purl.obolibrary.org/obo/HP_0002090"},{"id":"A24","pred":"hp_id","subj":"T24","obj":"http://purl.obolibrary.org/obo/HP_0001945"}],"text":"• Comparison of lopinavir/ritonavir vs. hydroxychloroquine in patients with mild COVID-19. Open-label RCT (NCT04307693, recruiting). Primary endpoint: virus load at day 3, 5, 7, 10, 14 and 18.\n• Comparison of ASC09/ritonavir vs. lopinavir/ritonavir in patients with confirmed COVID-19 pneumoniae. Open-label RCT (NCT04261907, not yet recruiting). Primary endpoint: adverse outcome at day 14 (composite of Spo 2 ≤ 93% without oxygen supplementation, PaO2/FiO2 ≤ 300 mm Hg or respiratory rate ≥ 30 breaths per minute).\n• Comparison of lopinavir/ritonavir vs. lopinavir/ritonavir plus umifenovir in patients with COVID-19. Open-label RCT (NCT04252885, recruiting). Primary endpoint: rate of virus inhibition at day 0, 2, 4, 7, 10, 14 and 21.\n• Comparison of lopinavir/ritonavir vs. lopinavir/ritonavir plus ribavirin plus interferon beta 1b in patients with COVID-19. Open-label RCT (NCT04276688, recruiting). Primary endpoint: time to negative nasopharyngeal swab RT-PCR (follow-up 30 days).\n• Comparison of only supportive treatment vs. lopinavir/ritonavir vs. oseltamivir vs. umifenovir in patients with confirmed COVID-19 pneumonia. Open-label RCT (NCT04255017, recruiting). Primary endpoints: (a) rate of disease remission (mild disease: fever, cough and other symptoms relieved with improved lung CT; severe disease: fever, cough and other symptoms relieved with improved lung CT, Spo 2 \u003e 93% or Pao 2/Fio 2 \u003e 300 mm Hg); (b) time to lung recovery.\n• Comparison of chemoprophylaxis with lopinavir/ritonavir vs. placebo in healthcare workers exposed to COVID-19. Double-blind RCT (NCT04328285, not yet recruiting). Primary endpoint: occurrence of a symptomatic or asymptomatic COVID-19 (follow-up 2.5 months).\n• Comparison of carrimycin vs. lopinavir/ritonavir or umifenovir or chloroquine in patients with COVID-19 pneumonia. Open-label RCT (NCT04286503, not yet recruiting). Primary endpoints: (a) fever to normal time (follow-up 30 days); (b) pulmonary inflammation resolution time (follow-up 30 days); (c) negative conversion of throat swab RT-PCR at EOT.\n• Comparison of lopinavir/ritonavir vs. lopinavir/ritonavir plus xiyanping (injectable component derived from a plant used in traditional Chinese medicine) in patients with COVID-19. Open-label RCT (NCT04295551, not yet recruiting). Primary endpoint: clinical recovery time (follow-up 28 days).\n• Comparison of lopinavir/ritonavir plus inhaled interferon alfa vs. lopinavir/ritonavir plus inhaled interferon alfa plus xiyanping injection in patients with COVID-19. Open-label RCT (NCT04275388, not yet recruiting). Primary endpoint: clinical recovery time (follow-up 14 days).\n• Comparison of lopinavir/ritonavir plus inhaled interferon alfa vs. lopinavir/ritonavir plus inhaled interferon alfa plus traditional Chinese medicines in patients with COVID-19. Open-label RCT (NCT04251871, recruiting). Primary endpoint: time to complete remission of symptoms (follow-up 28 days).\n• Comparison of lopinavir/ritonavir plus hydroxychloroquine vs. lopinavir/ritonavir plus hydroxychloroquine plus levamisole pill plus budesonide plus formoterol inhaler in patients with nonsevere COVID-19 pneumonia. Partly blinded RCT (NCT04331470, not yet recruiting). Primary endpoint: (a) clear CT scan at 3–7 days; (b) negative RT-PCR at 3–7 days.\n• Comparison of lopinavir/ritonavir vs. hydroxychloroquine vs. losartan vs. placebos in patients with COVID-19. Double-blind, adaptive RCT (NCT04328012, not yet recruiting). Primary endpoint: NIAID COVID-19 ordinal severity scale (follow-up 60 days).\n• Comparison of lopinavir/ritonavir vs. hydroxychloroquine vs. lopinavir/ritonavir plus interferon beta 1a vs. remdesivir vs. standard of care in patients with COVID-19. Double-blind, adaptive RCT (NCT04315948, recruiting). Primary endpoint: severity rating on a 7-point ordinal scale at day 15.\n• Comparison of lopinavir/ritonavir or umifenovir or chloroquine or hydroxychloroquine or oseltamivir (with or without azithromycin) vs. natural honey plus lopinavir/ritonavir or umifenovir or chloroquine or hydroxychloroquine or oseltamivir (with or without azithromycin) in patients with COVID-19. Single-blind RCT (NCT04323345, not yet recruiting). Primary endpoints: (a) positive to negative swabs at day 14; (b) fever to normal temperature in days (follow-up 14 days); (c) resolution of lung inflammation in CT or X-ray (follow-up 30 days).\n• Comparison of colchicine (with or without lopinavir/ritonavir) vs. local standard of care in patients with moderate to severe COVID-19. Open-label RCT (NCT04328480, not yet recruiting). Primary endpoint: all-cause mortality (follow-up 30 days).\n• Comparison of oseltamivir plus chloroquine vs. oseltamivir plus lopinavir/ritonavir in patients with mild COVID-19 and of lopinavir/ritonavir plus oseltamivir vs. darunavir/ritonavir plus oseltamivir vs. favipiravir plus lopinavir/ritonavir vs. darunavir/ritonavir plus oseltamivir plus chloroquine vs. darunavir/ritonavir plus favipiravir plus oseltamivir in patients with moderate to severe COVID-19. Open-label RCT (NCT04303299, not yet recruiting). Primary endpoint: SARS-CoV-2 eradication time (follow-up 24 weeks)."}
LitCovid-PD-MONDO
{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T76","span":{"begin":81,"end":89},"obj":"Disease"},{"id":"T77","span":{"begin":276,"end":284},"obj":"Disease"},{"id":"T78","span":{"begin":285,"end":295},"obj":"Disease"},{"id":"T79","span":{"begin":610,"end":618},"obj":"Disease"},{"id":"T80","span":{"begin":855,"end":863},"obj":"Disease"},{"id":"T81","span":{"begin":1114,"end":1122},"obj":"Disease"},{"id":"T82","span":{"begin":1123,"end":1132},"obj":"Disease"},{"id":"T83","span":{"begin":1555,"end":1563},"obj":"Disease"},{"id":"T84","span":{"begin":1679,"end":1687},"obj":"Disease"},{"id":"T85","span":{"begin":1809,"end":1817},"obj":"Disease"},{"id":"T86","span":{"begin":1818,"end":1827},"obj":"Disease"},{"id":"T87","span":{"begin":1958,"end":1970},"obj":"Disease"},{"id":"T88","span":{"begin":2235,"end":2243},"obj":"Disease"},{"id":"T89","span":{"begin":2517,"end":2525},"obj":"Disease"},{"id":"T90","span":{"begin":2809,"end":2817},"obj":"Disease"},{"id":"T91","span":{"begin":3135,"end":3143},"obj":"Disease"},{"id":"T92","span":{"begin":3144,"end":3153},"obj":"Disease"},{"id":"T93","span":{"begin":3393,"end":3401},"obj":"Disease"},{"id":"T94","span":{"begin":3489,"end":3497},"obj":"Disease"},{"id":"T95","span":{"begin":3702,"end":3710},"obj":"Disease"},{"id":"T96","span":{"begin":4128,"end":4136},"obj":"Disease"},{"id":"T97","span":{"begin":4335,"end":4347},"obj":"Disease"},{"id":"T98","span":{"begin":4512,"end":4520},"obj":"Disease"},{"id":"T99","span":{"begin":4739,"end":4747},"obj":"Disease"},{"id":"T100","span":{"begin":5026,"end":5034},"obj":"Disease"},{"id":"T101","span":{"begin":5104,"end":5112},"obj":"Disease"}],"attributes":[{"id":"A76","pred":"mondo_id","subj":"T76","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A77","pred":"mondo_id","subj":"T77","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A78","pred":"mondo_id","subj":"T78","obj":"http://purl.obolibrary.org/obo/MONDO_0005249"},{"id":"A79","pred":"mondo_id","subj":"T79","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A80","pred":"mondo_id","subj":"T80","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A81","pred":"mondo_id","subj":"T81","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A82","pred":"mondo_id","subj":"T82","obj":"http://purl.obolibrary.org/obo/MONDO_0005249"},{"id":"A83","pred":"mondo_id","subj":"T83","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A84","pred":"mondo_id","subj":"T84","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A85","pred":"mondo_id","subj":"T85","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A86","pred":"mondo_id","subj":"T86","obj":"http://purl.obolibrary.org/obo/MONDO_0005249"},{"id":"A87","pred":"mondo_id","subj":"T87","obj":"http://purl.obolibrary.org/obo/MONDO_0021166"},{"id":"A88","pred":"mondo_id","subj":"T88","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A89","pred":"mondo_id","subj":"T89","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A90","pred":"mondo_id","subj":"T90","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A91","pred":"mondo_id","subj":"T91","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A92","pred":"mondo_id","subj":"T92","obj":"http://purl.obolibrary.org/obo/MONDO_0005249"},{"id":"A93","pred":"mondo_id","subj":"T93","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A94","pred":"mondo_id","subj":"T94","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A95","pred":"mondo_id","subj":"T95","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A96","pred":"mondo_id","subj":"T96","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A97","pred":"mondo_id","subj":"T97","obj":"http://purl.obolibrary.org/obo/MONDO_0021166"},{"id":"A98","pred":"mondo_id","subj":"T98","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A99","pred":"mondo_id","subj":"T99","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A100","pred":"mondo_id","subj":"T100","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A101","pred":"mondo_id","subj":"T101","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"}],"text":"• Comparison of lopinavir/ritonavir vs. hydroxychloroquine in patients with mild COVID-19. Open-label RCT (NCT04307693, recruiting). Primary endpoint: virus load at day 3, 5, 7, 10, 14 and 18.\n• Comparison of ASC09/ritonavir vs. lopinavir/ritonavir in patients with confirmed COVID-19 pneumoniae. Open-label RCT (NCT04261907, not yet recruiting). Primary endpoint: adverse outcome at day 14 (composite of Spo 2 ≤ 93% without oxygen supplementation, PaO2/FiO2 ≤ 300 mm Hg or respiratory rate ≥ 30 breaths per minute).\n• Comparison of lopinavir/ritonavir vs. lopinavir/ritonavir plus umifenovir in patients with COVID-19. Open-label RCT (NCT04252885, recruiting). Primary endpoint: rate of virus inhibition at day 0, 2, 4, 7, 10, 14 and 21.\n• Comparison of lopinavir/ritonavir vs. lopinavir/ritonavir plus ribavirin plus interferon beta 1b in patients with COVID-19. Open-label RCT (NCT04276688, recruiting). Primary endpoint: time to negative nasopharyngeal swab RT-PCR (follow-up 30 days).\n• Comparison of only supportive treatment vs. lopinavir/ritonavir vs. oseltamivir vs. umifenovir in patients with confirmed COVID-19 pneumonia. Open-label RCT (NCT04255017, recruiting). Primary endpoints: (a) rate of disease remission (mild disease: fever, cough and other symptoms relieved with improved lung CT; severe disease: fever, cough and other symptoms relieved with improved lung CT, Spo 2 \u003e 93% or Pao 2/Fio 2 \u003e 300 mm Hg); (b) time to lung recovery.\n• Comparison of chemoprophylaxis with lopinavir/ritonavir vs. placebo in healthcare workers exposed to COVID-19. Double-blind RCT (NCT04328285, not yet recruiting). Primary endpoint: occurrence of a symptomatic or asymptomatic COVID-19 (follow-up 2.5 months).\n• Comparison of carrimycin vs. lopinavir/ritonavir or umifenovir or chloroquine in patients with COVID-19 pneumonia. Open-label RCT (NCT04286503, not yet recruiting). Primary endpoints: (a) fever to normal time (follow-up 30 days); (b) pulmonary inflammation resolution time (follow-up 30 days); (c) negative conversion of throat swab RT-PCR at EOT.\n• Comparison of lopinavir/ritonavir vs. lopinavir/ritonavir plus xiyanping (injectable component derived from a plant used in traditional Chinese medicine) in patients with COVID-19. Open-label RCT (NCT04295551, not yet recruiting). Primary endpoint: clinical recovery time (follow-up 28 days).\n• Comparison of lopinavir/ritonavir plus inhaled interferon alfa vs. lopinavir/ritonavir plus inhaled interferon alfa plus xiyanping injection in patients with COVID-19. Open-label RCT (NCT04275388, not yet recruiting). Primary endpoint: clinical recovery time (follow-up 14 days).\n• Comparison of lopinavir/ritonavir plus inhaled interferon alfa vs. lopinavir/ritonavir plus inhaled interferon alfa plus traditional Chinese medicines in patients with COVID-19. Open-label RCT (NCT04251871, recruiting). Primary endpoint: time to complete remission of symptoms (follow-up 28 days).\n• Comparison of lopinavir/ritonavir plus hydroxychloroquine vs. lopinavir/ritonavir plus hydroxychloroquine plus levamisole pill plus budesonide plus formoterol inhaler in patients with nonsevere COVID-19 pneumonia. Partly blinded RCT (NCT04331470, not yet recruiting). Primary endpoint: (a) clear CT scan at 3–7 days; (b) negative RT-PCR at 3–7 days.\n• Comparison of lopinavir/ritonavir vs. hydroxychloroquine vs. losartan vs. placebos in patients with COVID-19. Double-blind, adaptive RCT (NCT04328012, not yet recruiting). Primary endpoint: NIAID COVID-19 ordinal severity scale (follow-up 60 days).\n• Comparison of lopinavir/ritonavir vs. hydroxychloroquine vs. lopinavir/ritonavir plus interferon beta 1a vs. remdesivir vs. standard of care in patients with COVID-19. Double-blind, adaptive RCT (NCT04315948, recruiting). Primary endpoint: severity rating on a 7-point ordinal scale at day 15.\n• Comparison of lopinavir/ritonavir or umifenovir or chloroquine or hydroxychloroquine or oseltamivir (with or without azithromycin) vs. natural honey plus lopinavir/ritonavir or umifenovir or chloroquine or hydroxychloroquine or oseltamivir (with or without azithromycin) in patients with COVID-19. Single-blind RCT (NCT04323345, not yet recruiting). Primary endpoints: (a) positive to negative swabs at day 14; (b) fever to normal temperature in days (follow-up 14 days); (c) resolution of lung inflammation in CT or X-ray (follow-up 30 days).\n• Comparison of colchicine (with or without lopinavir/ritonavir) vs. local standard of care in patients with moderate to severe COVID-19. Open-label RCT (NCT04328480, not yet recruiting). Primary endpoint: all-cause mortality (follow-up 30 days).\n• Comparison of oseltamivir plus chloroquine vs. oseltamivir plus lopinavir/ritonavir in patients with mild COVID-19 and of lopinavir/ritonavir plus oseltamivir vs. darunavir/ritonavir plus oseltamivir vs. favipiravir plus lopinavir/ritonavir vs. darunavir/ritonavir plus oseltamivir plus chloroquine vs. darunavir/ritonavir plus favipiravir plus oseltamivir in patients with moderate to severe COVID-19. Open-label RCT (NCT04303299, not yet recruiting). Primary endpoint: SARS-CoV-2 eradication time (follow-up 24 weeks)."}
LitCovid-PD-CLO
{"project":"LitCovid-PD-CLO","denotations":[{"id":"T56","span":{"begin":96,"end":101},"obj":"http://purl.obolibrary.org/obo/CLO_0007225"},{"id":"T57","span":{"begin":151,"end":156},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_10239"},{"id":"T58","span":{"begin":169,"end":173},"obj":"http://purl.obolibrary.org/obo/CLO_0001000"},{"id":"T59","span":{"begin":189,"end":191},"obj":"http://purl.obolibrary.org/obo/CLO_0050510"},{"id":"T60","span":{"begin":302,"end":307},"obj":"http://purl.obolibrary.org/obo/CLO_0007225"},{"id":"T61","span":{"begin":409,"end":415},"obj":"http://purl.obolibrary.org/obo/CLO_0001230"},{"id":"T62","span":{"begin":409,"end":415},"obj":"http://purl.obolibrary.org/obo/CLO_0037237"},{"id":"T63","span":{"begin":409,"end":415},"obj":"http://purl.obolibrary.org/obo/CLO_0050903"},{"id":"T64","span":{"begin":409,"end":415},"obj":"http://purl.obolibrary.org/obo/CLO_0054249"},{"id":"T65","span":{"begin":409,"end":415},"obj":"http://purl.obolibrary.org/obo/CLO_0054250"},{"id":"T66","span":{"begin":409,"end":415},"obj":"http://purl.obolibrary.org/obo/CLO_0054251"},{"id":"T67","span":{"begin":409,"end":415},"obj":"http://purl.obolibrary.org/obo/CLO_0054252"},{"id":"T68","span":{"begin":625,"end":630},"obj":"http://purl.obolibrary.org/obo/CLO_0007225"},{"id":"T69","span":{"begin":688,"end":693},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_10239"},{"id":"T70","span":{"begin":870,"end":875},"obj":"http://purl.obolibrary.org/obo/CLO_0007225"},{"id":"T71","span":{"begin":1139,"end":1144},"obj":"http://purl.obolibrary.org/obo/CLO_0007225"},{"id":"T72","span":{"begin":1196,"end":1197},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T73","span":{"begin":1295,"end":1299},"obj":"http://purl.obolibrary.org/obo/UBERON_0002048"},{"id":"T74","span":{"begin":1295,"end":1299},"obj":"http://www.ebi.ac.uk/efo/EFO_0000934"},{"id":"T75","span":{"begin":1375,"end":1379},"obj":"http://purl.obolibrary.org/obo/UBERON_0002048"},{"id":"T76","span":{"begin":1375,"end":1379},"obj":"http://www.ebi.ac.uk/efo/EFO_0000934"},{"id":"T77","span":{"begin":1388,"end":1394},"obj":"http://purl.obolibrary.org/obo/CLO_0001230"},{"id":"T78","span":{"begin":1388,"end":1394},"obj":"http://purl.obolibrary.org/obo/CLO_0037237"},{"id":"T79","span":{"begin":1388,"end":1394},"obj":"http://purl.obolibrary.org/obo/CLO_0050903"},{"id":"T80","span":{"begin":1388,"end":1394},"obj":"http://purl.obolibrary.org/obo/CLO_0054249"},{"id":"T81","span":{"begin":1388,"end":1394},"obj":"http://purl.obolibrary.org/obo/CLO_0054250"},{"id":"T82","span":{"begin":1388,"end":1394},"obj":"http://purl.obolibrary.org/obo/CLO_0054251"},{"id":"T83","span":{"begin":1388,"end":1394},"obj":"http://purl.obolibrary.org/obo/CLO_0054252"},{"id":"T84","span":{"begin":1426,"end":1427},"obj":"http://purl.obolibrary.org/obo/CLO_0001021"},{"id":"T85","span":{"begin":1437,"end":1441},"obj":"http://purl.obolibrary.org/obo/UBERON_0002048"},{"id":"T86","span":{"begin":1437,"end":1441},"obj":"http://www.ebi.ac.uk/efo/EFO_0000934"},{"id":"T87","span":{"begin":1649,"end":1650},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T88","span":{"begin":1834,"end":1839},"obj":"http://purl.obolibrary.org/obo/CLO_0007225"},{"id":"T89","span":{"begin":1899,"end":1900},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T90","span":{"begin":1945,"end":1946},"obj":"http://purl.obolibrary.org/obo/CLO_0001021"},{"id":"T91","span":{"begin":2172,"end":2173},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T92","span":{"begin":2250,"end":2255},"obj":"http://purl.obolibrary.org/obo/CLO_0007225"},{"id":"T93","span":{"begin":2532,"end":2537},"obj":"http://purl.obolibrary.org/obo/CLO_0007225"},{"id":"T94","span":{"begin":2824,"end":2829},"obj":"http://purl.obolibrary.org/obo/CLO_0007225"},{"id":"T95","span":{"begin":3228,"end":3229},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T96","span":{"begin":3259,"end":3260},"obj":"http://purl.obolibrary.org/obo/CLO_0001021"},{"id":"T97","span":{"begin":3803,"end":3806},"obj":"http://purl.obolibrary.org/obo/CLO_0001608"},{"id":"T98","span":{"begin":4210,"end":4211},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T99","span":{"begin":4252,"end":4253},"obj":"http://purl.obolibrary.org/obo/CLO_0001021"},{"id":"T100","span":{"begin":4330,"end":4334},"obj":"http://purl.obolibrary.org/obo/UBERON_0002048"},{"id":"T101","span":{"begin":4330,"end":4334},"obj":"http://www.ebi.ac.uk/efo/EFO_0000934"},{"id":"T102","span":{"begin":4527,"end":4532},"obj":"http://purl.obolibrary.org/obo/CLO_0007225"},{"id":"T103","span":{"begin":5041,"end":5046},"obj":"http://purl.obolibrary.org/obo/CLO_0007225"}],"text":"• Comparison of lopinavir/ritonavir vs. hydroxychloroquine in patients with mild COVID-19. Open-label RCT (NCT04307693, recruiting). Primary endpoint: virus load at day 3, 5, 7, 10, 14 and 18.\n• Comparison of ASC09/ritonavir vs. lopinavir/ritonavir in patients with confirmed COVID-19 pneumoniae. Open-label RCT (NCT04261907, not yet recruiting). Primary endpoint: adverse outcome at day 14 (composite of Spo 2 ≤ 93% without oxygen supplementation, PaO2/FiO2 ≤ 300 mm Hg or respiratory rate ≥ 30 breaths per minute).\n• Comparison of lopinavir/ritonavir vs. lopinavir/ritonavir plus umifenovir in patients with COVID-19. Open-label RCT (NCT04252885, recruiting). Primary endpoint: rate of virus inhibition at day 0, 2, 4, 7, 10, 14 and 21.\n• Comparison of lopinavir/ritonavir vs. lopinavir/ritonavir plus ribavirin plus interferon beta 1b in patients with COVID-19. Open-label RCT (NCT04276688, recruiting). Primary endpoint: time to negative nasopharyngeal swab RT-PCR (follow-up 30 days).\n• Comparison of only supportive treatment vs. lopinavir/ritonavir vs. oseltamivir vs. umifenovir in patients with confirmed COVID-19 pneumonia. Open-label RCT (NCT04255017, recruiting). Primary endpoints: (a) rate of disease remission (mild disease: fever, cough and other symptoms relieved with improved lung CT; severe disease: fever, cough and other symptoms relieved with improved lung CT, Spo 2 \u003e 93% or Pao 2/Fio 2 \u003e 300 mm Hg); (b) time to lung recovery.\n• Comparison of chemoprophylaxis with lopinavir/ritonavir vs. placebo in healthcare workers exposed to COVID-19. Double-blind RCT (NCT04328285, not yet recruiting). Primary endpoint: occurrence of a symptomatic or asymptomatic COVID-19 (follow-up 2.5 months).\n• Comparison of carrimycin vs. lopinavir/ritonavir or umifenovir or chloroquine in patients with COVID-19 pneumonia. Open-label RCT (NCT04286503, not yet recruiting). Primary endpoints: (a) fever to normal time (follow-up 30 days); (b) pulmonary inflammation resolution time (follow-up 30 days); (c) negative conversion of throat swab RT-PCR at EOT.\n• Comparison of lopinavir/ritonavir vs. lopinavir/ritonavir plus xiyanping (injectable component derived from a plant used in traditional Chinese medicine) in patients with COVID-19. Open-label RCT (NCT04295551, not yet recruiting). Primary endpoint: clinical recovery time (follow-up 28 days).\n• Comparison of lopinavir/ritonavir plus inhaled interferon alfa vs. lopinavir/ritonavir plus inhaled interferon alfa plus xiyanping injection in patients with COVID-19. Open-label RCT (NCT04275388, not yet recruiting). Primary endpoint: clinical recovery time (follow-up 14 days).\n• Comparison of lopinavir/ritonavir plus inhaled interferon alfa vs. lopinavir/ritonavir plus inhaled interferon alfa plus traditional Chinese medicines in patients with COVID-19. Open-label RCT (NCT04251871, recruiting). Primary endpoint: time to complete remission of symptoms (follow-up 28 days).\n• Comparison of lopinavir/ritonavir plus hydroxychloroquine vs. lopinavir/ritonavir plus hydroxychloroquine plus levamisole pill plus budesonide plus formoterol inhaler in patients with nonsevere COVID-19 pneumonia. Partly blinded RCT (NCT04331470, not yet recruiting). Primary endpoint: (a) clear CT scan at 3–7 days; (b) negative RT-PCR at 3–7 days.\n• Comparison of lopinavir/ritonavir vs. hydroxychloroquine vs. losartan vs. placebos in patients with COVID-19. Double-blind, adaptive RCT (NCT04328012, not yet recruiting). Primary endpoint: NIAID COVID-19 ordinal severity scale (follow-up 60 days).\n• Comparison of lopinavir/ritonavir vs. hydroxychloroquine vs. lopinavir/ritonavir plus interferon beta 1a vs. remdesivir vs. standard of care in patients with COVID-19. Double-blind, adaptive RCT (NCT04315948, recruiting). Primary endpoint: severity rating on a 7-point ordinal scale at day 15.\n• Comparison of lopinavir/ritonavir or umifenovir or chloroquine or hydroxychloroquine or oseltamivir (with or without azithromycin) vs. natural honey plus lopinavir/ritonavir or umifenovir or chloroquine or hydroxychloroquine or oseltamivir (with or without azithromycin) in patients with COVID-19. Single-blind RCT (NCT04323345, not yet recruiting). Primary endpoints: (a) positive to negative swabs at day 14; (b) fever to normal temperature in days (follow-up 14 days); (c) resolution of lung inflammation in CT or X-ray (follow-up 30 days).\n• Comparison of colchicine (with or without lopinavir/ritonavir) vs. local standard of care in patients with moderate to severe COVID-19. Open-label RCT (NCT04328480, not yet recruiting). Primary endpoint: all-cause mortality (follow-up 30 days).\n• Comparison of oseltamivir plus chloroquine vs. oseltamivir plus lopinavir/ritonavir in patients with mild COVID-19 and of lopinavir/ritonavir plus oseltamivir vs. darunavir/ritonavir plus oseltamivir vs. favipiravir plus lopinavir/ritonavir vs. darunavir/ritonavir plus oseltamivir plus chloroquine vs. darunavir/ritonavir plus favipiravir plus oseltamivir in patients with moderate to severe COVID-19. Open-label RCT (NCT04303299, not yet recruiting). Primary endpoint: SARS-CoV-2 eradication time (follow-up 24 weeks)."}
LitCovid-PD-CHEBI
{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T87","span":{"begin":16,"end":35},"obj":"Chemical"},{"id":"T88","span":{"begin":16,"end":25},"obj":"Chemical"},{"id":"T89","span":{"begin":26,"end":35},"obj":"Chemical"},{"id":"T90","span":{"begin":40,"end":58},"obj":"Chemical"},{"id":"T91","span":{"begin":96,"end":101},"obj":"Chemical"},{"id":"T92","span":{"begin":215,"end":224},"obj":"Chemical"},{"id":"T93","span":{"begin":229,"end":248},"obj":"Chemical"},{"id":"T94","span":{"begin":229,"end":238},"obj":"Chemical"},{"id":"T95","span":{"begin":239,"end":248},"obj":"Chemical"},{"id":"T96","span":{"begin":302,"end":307},"obj":"Chemical"},{"id":"T97","span":{"begin":425,"end":431},"obj":"Chemical"},{"id":"T98","span":{"begin":468,"end":470},"obj":"Chemical"},{"id":"T100","span":{"begin":533,"end":552},"obj":"Chemical"},{"id":"T101","span":{"begin":533,"end":542},"obj":"Chemical"},{"id":"T102","span":{"begin":543,"end":552},"obj":"Chemical"},{"id":"T103","span":{"begin":557,"end":576},"obj":"Chemical"},{"id":"T104","span":{"begin":557,"end":566},"obj":"Chemical"},{"id":"T105","span":{"begin":567,"end":576},"obj":"Chemical"},{"id":"T106","span":{"begin":582,"end":592},"obj":"Chemical"},{"id":"T107","span":{"begin":625,"end":630},"obj":"Chemical"},{"id":"T108","span":{"begin":755,"end":774},"obj":"Chemical"},{"id":"T109","span":{"begin":755,"end":764},"obj":"Chemical"},{"id":"T110","span":{"begin":765,"end":774},"obj":"Chemical"},{"id":"T111","span":{"begin":779,"end":798},"obj":"Chemical"},{"id":"T112","span":{"begin":779,"end":788},"obj":"Chemical"},{"id":"T113","span":{"begin":789,"end":798},"obj":"Chemical"},{"id":"T114","span":{"begin":804,"end":813},"obj":"Chemical"},{"id":"T115","span":{"begin":819,"end":829},"obj":"Chemical"},{"id":"T116","span":{"begin":830,"end":834},"obj":"Chemical"},{"id":"T117","span":{"begin":870,"end":875},"obj":"Chemical"},{"id":"T118","span":{"begin":1036,"end":1055},"obj":"Chemical"},{"id":"T119","span":{"begin":1036,"end":1045},"obj":"Chemical"},{"id":"T120","span":{"begin":1046,"end":1055},"obj":"Chemical"},{"id":"T121","span":{"begin":1060,"end":1071},"obj":"Chemical"},{"id":"T122","span":{"begin":1076,"end":1086},"obj":"Chemical"},{"id":"T123","span":{"begin":1139,"end":1144},"obj":"Chemical"},{"id":"T124","span":{"begin":1420,"end":1422},"obj":"Chemical"},{"id":"T126","span":{"begin":1490,"end":1509},"obj":"Chemical"},{"id":"T127","span":{"begin":1490,"end":1499},"obj":"Chemical"},{"id":"T128","span":{"begin":1500,"end":1509},"obj":"Chemical"},{"id":"T129","span":{"begin":1743,"end":1762},"obj":"Chemical"},{"id":"T130","span":{"begin":1743,"end":1752},"obj":"Chemical"},{"id":"T131","span":{"begin":1753,"end":1762},"obj":"Chemical"},{"id":"T132","span":{"begin":1766,"end":1776},"obj":"Chemical"},{"id":"T133","span":{"begin":1780,"end":1791},"obj":"Chemical"},{"id":"T134","span":{"begin":1834,"end":1839},"obj":"Chemical"},{"id":"T135","span":{"begin":2078,"end":2097},"obj":"Chemical"},{"id":"T136","span":{"begin":2078,"end":2087},"obj":"Chemical"},{"id":"T137","span":{"begin":2088,"end":2097},"obj":"Chemical"},{"id":"T138","span":{"begin":2102,"end":2121},"obj":"Chemical"},{"id":"T139","span":{"begin":2102,"end":2111},"obj":"Chemical"},{"id":"T140","span":{"begin":2112,"end":2121},"obj":"Chemical"},{"id":"T141","span":{"begin":2208,"end":2216},"obj":"Chemical"},{"id":"T142","span":{"begin":2250,"end":2255},"obj":"Chemical"},{"id":"T143","span":{"begin":2373,"end":2392},"obj":"Chemical"},{"id":"T144","span":{"begin":2373,"end":2382},"obj":"Chemical"},{"id":"T145","span":{"begin":2383,"end":2392},"obj":"Chemical"},{"id":"T146","span":{"begin":2406,"end":2416},"obj":"Chemical"},{"id":"T147","span":{"begin":2426,"end":2445},"obj":"Chemical"},{"id":"T148","span":{"begin":2426,"end":2435},"obj":"Chemical"},{"id":"T149","span":{"begin":2436,"end":2445},"obj":"Chemical"},{"id":"T150","span":{"begin":2459,"end":2469},"obj":"Chemical"},{"id":"T151","span":{"begin":2532,"end":2537},"obj":"Chemical"},{"id":"T152","span":{"begin":2655,"end":2674},"obj":"Chemical"},{"id":"T153","span":{"begin":2655,"end":2664},"obj":"Chemical"},{"id":"T154","span":{"begin":2665,"end":2674},"obj":"Chemical"},{"id":"T155","span":{"begin":2688,"end":2698},"obj":"Chemical"},{"id":"T156","span":{"begin":2708,"end":2727},"obj":"Chemical"},{"id":"T157","span":{"begin":2708,"end":2717},"obj":"Chemical"},{"id":"T158","span":{"begin":2718,"end":2727},"obj":"Chemical"},{"id":"T159","span":{"begin":2741,"end":2751},"obj":"Chemical"},{"id":"T160","span":{"begin":2824,"end":2829},"obj":"Chemical"},{"id":"T161","span":{"begin":2955,"end":2974},"obj":"Chemical"},{"id":"T162","span":{"begin":2955,"end":2964},"obj":"Chemical"},{"id":"T163","span":{"begin":2965,"end":2974},"obj":"Chemical"},{"id":"T164","span":{"begin":2980,"end":2998},"obj":"Chemical"},{"id":"T165","span":{"begin":3003,"end":3022},"obj":"Chemical"},{"id":"T166","span":{"begin":3003,"end":3012},"obj":"Chemical"},{"id":"T167","span":{"begin":3013,"end":3022},"obj":"Chemical"},{"id":"T168","span":{"begin":3028,"end":3046},"obj":"Chemical"},{"id":"T169","span":{"begin":3052,"end":3062},"obj":"Chemical"},{"id":"T170","span":{"begin":3073,"end":3083},"obj":"Chemical"},{"id":"T171","span":{"begin":3089,"end":3099},"obj":"Chemical"},{"id":"T172","span":{"begin":3307,"end":3326},"obj":"Chemical"},{"id":"T173","span":{"begin":3307,"end":3316},"obj":"Chemical"},{"id":"T174","span":{"begin":3317,"end":3326},"obj":"Chemical"},{"id":"T175","span":{"begin":3331,"end":3349},"obj":"Chemical"},{"id":"T176","span":{"begin":3354,"end":3362},"obj":"Chemical"},{"id":"T177","span":{"begin":3558,"end":3577},"obj":"Chemical"},{"id":"T178","span":{"begin":3558,"end":3567},"obj":"Chemical"},{"id":"T179","span":{"begin":3568,"end":3577},"obj":"Chemical"},{"id":"T180","span":{"begin":3582,"end":3600},"obj":"Chemical"},{"id":"T181","span":{"begin":3605,"end":3624},"obj":"Chemical"},{"id":"T182","span":{"begin":3605,"end":3614},"obj":"Chemical"},{"id":"T183","span":{"begin":3615,"end":3624},"obj":"Chemical"},{"id":"T184","span":{"begin":3630,"end":3640},"obj":"Chemical"},{"id":"T185","span":{"begin":3641,"end":3645},"obj":"Chemical"},{"id":"T186","span":{"begin":3653,"end":3663},"obj":"Chemical"},{"id":"T187","span":{"begin":3854,"end":3873},"obj":"Chemical"},{"id":"T188","span":{"begin":3854,"end":3863},"obj":"Chemical"},{"id":"T189","span":{"begin":3864,"end":3873},"obj":"Chemical"},{"id":"T190","span":{"begin":3877,"end":3887},"obj":"Chemical"},{"id":"T191","span":{"begin":3891,"end":3902},"obj":"Chemical"},{"id":"T192","span":{"begin":3906,"end":3924},"obj":"Chemical"},{"id":"T193","span":{"begin":3928,"end":3939},"obj":"Chemical"},{"id":"T194","span":{"begin":3957,"end":3969},"obj":"Chemical"},{"id":"T195","span":{"begin":3994,"end":4013},"obj":"Chemical"},{"id":"T196","span":{"begin":3994,"end":4003},"obj":"Chemical"},{"id":"T197","span":{"begin":4004,"end":4013},"obj":"Chemical"},{"id":"T198","span":{"begin":4017,"end":4027},"obj":"Chemical"},{"id":"T199","span":{"begin":4031,"end":4042},"obj":"Chemical"},{"id":"T200","span":{"begin":4046,"end":4064},"obj":"Chemical"},{"id":"T201","span":{"begin":4068,"end":4079},"obj":"Chemical"},{"id":"T202","span":{"begin":4097,"end":4109},"obj":"Chemical"},{"id":"T203","span":{"begin":4400,"end":4410},"obj":"Chemical"},{"id":"T204","span":{"begin":4428,"end":4447},"obj":"Chemical"},{"id":"T205","span":{"begin":4428,"end":4437},"obj":"Chemical"},{"id":"T206","span":{"begin":4438,"end":4447},"obj":"Chemical"},{"id":"T207","span":{"begin":4527,"end":4532},"obj":"Chemical"},{"id":"T208","span":{"begin":4647,"end":4658},"obj":"Chemical"},{"id":"T209","span":{"begin":4664,"end":4675},"obj":"Chemical"},{"id":"T210","span":{"begin":4680,"end":4691},"obj":"Chemical"},{"id":"T211","span":{"begin":4697,"end":4716},"obj":"Chemical"},{"id":"T212","span":{"begin":4697,"end":4706},"obj":"Chemical"},{"id":"T213","span":{"begin":4707,"end":4716},"obj":"Chemical"},{"id":"T214","span":{"begin":4755,"end":4774},"obj":"Chemical"},{"id":"T215","span":{"begin":4755,"end":4764},"obj":"Chemical"},{"id":"T216","span":{"begin":4765,"end":4774},"obj":"Chemical"},{"id":"T217","span":{"begin":4780,"end":4791},"obj":"Chemical"},{"id":"T218","span":{"begin":4796,"end":4805},"obj":"Chemical"},{"id":"T219","span":{"begin":4806,"end":4815},"obj":"Chemical"},{"id":"T220","span":{"begin":4821,"end":4832},"obj":"Chemical"},{"id":"T221","span":{"begin":4837,"end":4848},"obj":"Chemical"},{"id":"T222","span":{"begin":4854,"end":4873},"obj":"Chemical"},{"id":"T223","span":{"begin":4854,"end":4863},"obj":"Chemical"},{"id":"T224","span":{"begin":4864,"end":4873},"obj":"Chemical"},{"id":"T225","span":{"begin":4878,"end":4887},"obj":"Chemical"},{"id":"T226","span":{"begin":4888,"end":4897},"obj":"Chemical"},{"id":"T227","span":{"begin":4903,"end":4914},"obj":"Chemical"},{"id":"T228","span":{"begin":4920,"end":4931},"obj":"Chemical"},{"id":"T229","span":{"begin":4936,"end":4945},"obj":"Chemical"},{"id":"T230","span":{"begin":4946,"end":4955},"obj":"Chemical"},{"id":"T231","span":{"begin":4961,"end":4972},"obj":"Chemical"},{"id":"T232","span":{"begin":4978,"end":4989},"obj":"Chemical"},{"id":"T233","span":{"begin":5041,"end":5046},"obj":"Chemical"}],"attributes":[{"id":"A87","pred":"chebi_id","subj":"T87","obj":"http://purl.obolibrary.org/obo/CHEBI_145924"},{"id":"A88","pred":"chebi_id","subj":"T88","obj":"http://purl.obolibrary.org/obo/CHEBI_31781"},{"id":"A89","pred":"chebi_id","subj":"T89","obj":"http://purl.obolibrary.org/obo/CHEBI_45409"},{"id":"A90","pred":"chebi_id","subj":"T90","obj":"http://purl.obolibrary.org/obo/CHEBI_5801"},{"id":"A91","pred":"chebi_id","subj":"T91","obj":"http://purl.obolibrary.org/obo/CHEBI_35209"},{"id":"A92","pred":"chebi_id","subj":"T92","obj":"http://purl.obolibrary.org/obo/CHEBI_45409"},{"id":"A93","pred":"chebi_id","subj":"T93","obj":"http://purl.obolibrary.org/obo/CHEBI_145924"},{"id":"A94","pred":"chebi_id","subj":"T94","obj":"http://purl.obolibrary.org/obo/CHEBI_31781"},{"id":"A95","pred":"chebi_id","subj":"T95","obj":"http://purl.obolibrary.org/obo/CHEBI_45409"},{"id":"A96","pred":"chebi_id","subj":"T96","obj":"http://purl.obolibrary.org/obo/CHEBI_35209"},{"id":"A97","pred":"chebi_id","subj":"T97","obj":"http://purl.obolibrary.org/obo/CHEBI_25805"},{"id":"A98","pred":"chebi_id","subj":"T98","obj":"http://purl.obolibrary.org/obo/CHEBI_16170"},{"id":"A99","pred":"chebi_id","subj":"T98","obj":"http://purl.obolibrary.org/obo/CHEBI_25195"},{"id":"A100","pred":"chebi_id","subj":"T100","obj":"http://purl.obolibrary.org/obo/CHEBI_145924"},{"id":"A101","pred":"chebi_id","subj":"T101","obj":"http://purl.obolibrary.org/obo/CHEBI_31781"},{"id":"A102","pred":"chebi_id","subj":"T102","obj":"http://purl.obolibrary.org/obo/CHEBI_45409"},{"id":"A103","pred":"chebi_id","subj":"T103","obj":"http://purl.obolibrary.org/obo/CHEBI_145924"},{"id":"A104","pred":"chebi_id","subj":"T104","obj":"http://purl.obolibrary.org/obo/CHEBI_31781"},{"id":"A105","pred":"chebi_id","subj":"T105","obj":"http://purl.obolibrary.org/obo/CHEBI_45409"},{"id":"A106","pred":"chebi_id","subj":"T106","obj":"http://purl.obolibrary.org/obo/CHEBI_134730"},{"id":"A107","pred":"chebi_id","subj":"T107","obj":"http://purl.obolibrary.org/obo/CHEBI_35209"},{"id":"A108","pred":"chebi_id","subj":"T108","obj":"http://purl.obolibrary.org/obo/CHEBI_145924"},{"id":"A109","pred":"chebi_id","subj":"T109","obj":"http://purl.obolibrary.org/obo/CHEBI_31781"},{"id":"A110","pred":"chebi_id","subj":"T110","obj":"http://purl.obolibrary.org/obo/CHEBI_45409"},{"id":"A111","pred":"chebi_id","subj":"T111","obj":"http://purl.obolibrary.org/obo/CHEBI_145924"},{"id":"A112","pred":"chebi_id","subj":"T112","obj":"http://purl.obolibrary.org/obo/CHEBI_31781"},{"id":"A113","pred":"chebi_id","subj":"T113","obj":"http://purl.obolibrary.org/obo/CHEBI_45409"},{"id":"A114","pred":"chebi_id","subj":"T114","obj":"http://purl.obolibrary.org/obo/CHEBI_63580"},{"id":"A115","pred":"chebi_id","subj":"T115","obj":"http://purl.obolibrary.org/obo/CHEBI_52999"},{"id":"A116","pred":"chebi_id","subj":"T116","obj":"http://purl.obolibrary.org/obo/CHEBI_10545"},{"id":"A117","pred":"chebi_id","subj":"T117","obj":"http://purl.obolibrary.org/obo/CHEBI_35209"},{"id":"A118","pred":"chebi_id","subj":"T118","obj":"http://purl.obolibrary.org/obo/CHEBI_145924"},{"id":"A119","pred":"chebi_id","subj":"T119","obj":"http://purl.obolibrary.org/obo/CHEBI_31781"},{"id":"A120","pred":"chebi_id","subj":"T120","obj":"http://purl.obolibrary.org/obo/CHEBI_45409"},{"id":"A121","pred":"chebi_id","subj":"T121","obj":"http://purl.obolibrary.org/obo/CHEBI_7798"},{"id":"A122","pred":"chebi_id","subj":"T122","obj":"http://purl.obolibrary.org/obo/CHEBI_134730"},{"id":"A123","pred":"chebi_id","subj":"T123","obj":"http://purl.obolibrary.org/obo/CHEBI_35209"},{"id":"A124","pred":"chebi_id","subj":"T124","obj":"http://purl.obolibrary.org/obo/CHEBI_16170"},{"id":"A125","pred":"chebi_id","subj":"T124","obj":"http://purl.obolibrary.org/obo/CHEBI_25195"},{"id":"A126","pred":"chebi_id","subj":"T126","obj":"http://purl.obolibrary.org/obo/CHEBI_145924"},{"id":"A127","pred":"chebi_id","subj":"T127","obj":"http://purl.obolibrary.org/obo/CHEBI_31781"},{"id":"A128","pred":"chebi_id","subj":"T128","obj":"http://purl.obolibrary.org/obo/CHEBI_45409"},{"id":"A129","pred":"chebi_id","subj":"T129","obj":"http://purl.obolibrary.org/obo/CHEBI_145924"},{"id":"A130","pred":"chebi_id","subj":"T130","obj":"http://purl.obolibrary.org/obo/CHEBI_31781"},{"id":"A131","pred":"chebi_id","subj":"T131","obj":"http://purl.obolibrary.org/obo/CHEBI_45409"},{"id":"A132","pred":"chebi_id","subj":"T132","obj":"http://purl.obolibrary.org/obo/CHEBI_134730"},{"id":"A133","pred":"chebi_id","subj":"T133","obj":"http://purl.obolibrary.org/obo/CHEBI_3638"},{"id":"A134","pred":"chebi_id","subj":"T134","obj":"http://purl.obolibrary.org/obo/CHEBI_35209"},{"id":"A135","pred":"chebi_id","subj":"T135","obj":"http://purl.obolibrary.org/obo/CHEBI_145924"},{"id":"A136","pred":"chebi_id","subj":"T136","obj":"http://purl.obolibrary.org/obo/CHEBI_31781"},{"id":"A137","pred":"chebi_id","subj":"T137","obj":"http://purl.obolibrary.org/obo/CHEBI_45409"},{"id":"A138","pred":"chebi_id","subj":"T138","obj":"http://purl.obolibrary.org/obo/CHEBI_145924"},{"id":"A139","pred":"chebi_id","subj":"T139","obj":"http://purl.obolibrary.org/obo/CHEBI_31781"},{"id":"A140","pred":"chebi_id","subj":"T140","obj":"http://purl.obolibrary.org/obo/CHEBI_45409"},{"id":"A141","pred":"chebi_id","subj":"T141","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"},{"id":"A142","pred":"chebi_id","subj":"T142","obj":"http://purl.obolibrary.org/obo/CHEBI_35209"},{"id":"A143","pred":"chebi_id","subj":"T143","obj":"http://purl.obolibrary.org/obo/CHEBI_145924"},{"id":"A144","pred":"chebi_id","subj":"T144","obj":"http://purl.obolibrary.org/obo/CHEBI_31781"},{"id":"A145","pred":"chebi_id","subj":"T145","obj":"http://purl.obolibrary.org/obo/CHEBI_45409"},{"id":"A146","pred":"chebi_id","subj":"T146","obj":"http://purl.obolibrary.org/obo/CHEBI_52999"},{"id":"A147","pred":"chebi_id","subj":"T147","obj":"http://purl.obolibrary.org/obo/CHEBI_145924"},{"id":"A148","pred":"chebi_id","subj":"T148","obj":"http://purl.obolibrary.org/obo/CHEBI_31781"},{"id":"A149","pred":"chebi_id","subj":"T149","obj":"http://purl.obolibrary.org/obo/CHEBI_45409"},{"id":"A150","pred":"chebi_id","subj":"T150","obj":"http://purl.obolibrary.org/obo/CHEBI_52999"},{"id":"A151","pred":"chebi_id","subj":"T151","obj":"http://purl.obolibrary.org/obo/CHEBI_35209"},{"id":"A152","pred":"chebi_id","subj":"T152","obj":"http://purl.obolibrary.org/obo/CHEBI_145924"},{"id":"A153","pred":"chebi_id","subj":"T153","obj":"http://purl.obolibrary.org/obo/CHEBI_31781"},{"id":"A154","pred":"chebi_id","subj":"T154","obj":"http://purl.obolibrary.org/obo/CHEBI_45409"},{"id":"A155","pred":"chebi_id","subj":"T155","obj":"http://purl.obolibrary.org/obo/CHEBI_52999"},{"id":"A156","pred":"chebi_id","subj":"T156","obj":"http://purl.obolibrary.org/obo/CHEBI_145924"},{"id":"A157","pred":"chebi_id","subj":"T157","obj":"http://purl.obolibrary.org/obo/CHEBI_31781"},{"id":"A158","pred":"chebi_id","subj":"T158","obj":"http://purl.obolibrary.org/obo/CHEBI_45409"},{"id":"A159","pred":"chebi_id","subj":"T159","obj":"http://purl.obolibrary.org/obo/CHEBI_52999"},{"id":"A160","pred":"chebi_id","subj":"T160","obj":"http://purl.obolibrary.org/obo/CHEBI_35209"},{"id":"A161","pred":"chebi_id","subj":"T161","obj":"http://purl.obolibrary.org/obo/CHEBI_145924"},{"id":"A162","pred":"chebi_id","subj":"T162","obj":"http://purl.obolibrary.org/obo/CHEBI_31781"},{"id":"A163","pred":"chebi_id","subj":"T163","obj":"http://purl.obolibrary.org/obo/CHEBI_45409"},{"id":"A164","pred":"chebi_id","subj":"T164","obj":"http://purl.obolibrary.org/obo/CHEBI_5801"},{"id":"A165","pred":"chebi_id","subj":"T165","obj":"http://purl.obolibrary.org/obo/CHEBI_145924"},{"id":"A166","pred":"chebi_id","subj":"T166","obj":"http://purl.obolibrary.org/obo/CHEBI_31781"},{"id":"A167","pred":"chebi_id","subj":"T167","obj":"http://purl.obolibrary.org/obo/CHEBI_45409"},{"id":"A168","pred":"chebi_id","subj":"T168","obj":"http://purl.obolibrary.org/obo/CHEBI_5801"},{"id":"A169","pred":"chebi_id","subj":"T169","obj":"http://purl.obolibrary.org/obo/CHEBI_6432"},{"id":"A170","pred":"chebi_id","subj":"T170","obj":"http://purl.obolibrary.org/obo/CHEBI_3207"},{"id":"A171","pred":"chebi_id","subj":"T171","obj":"http://purl.obolibrary.org/obo/CHEBI_5147"},{"id":"A172","pred":"chebi_id","subj":"T172","obj":"http://purl.obolibrary.org/obo/CHEBI_145924"},{"id":"A173","pred":"chebi_id","subj":"T173","obj":"http://purl.obolibrary.org/obo/CHEBI_31781"},{"id":"A174","pred":"chebi_id","subj":"T174","obj":"http://purl.obolibrary.org/obo/CHEBI_45409"},{"id":"A175","pred":"chebi_id","subj":"T175","obj":"http://purl.obolibrary.org/obo/CHEBI_5801"},{"id":"A176","pred":"chebi_id","subj":"T176","obj":"http://purl.obolibrary.org/obo/CHEBI_6541"},{"id":"A177","pred":"chebi_id","subj":"T177","obj":"http://purl.obolibrary.org/obo/CHEBI_145924"},{"id":"A178","pred":"chebi_id","subj":"T178","obj":"http://purl.obolibrary.org/obo/CHEBI_31781"},{"id":"A179","pred":"chebi_id","subj":"T179","obj":"http://purl.obolibrary.org/obo/CHEBI_45409"},{"id":"A180","pred":"chebi_id","subj":"T180","obj":"http://purl.obolibrary.org/obo/CHEBI_5801"},{"id":"A181","pred":"chebi_id","subj":"T181","obj":"http://purl.obolibrary.org/obo/CHEBI_145924"},{"id":"A182","pred":"chebi_id","subj":"T182","obj":"http://purl.obolibrary.org/obo/CHEBI_31781"},{"id":"A183","pred":"chebi_id","subj":"T183","obj":"http://purl.obolibrary.org/obo/CHEBI_45409"},{"id":"A184","pred":"chebi_id","subj":"T184","obj":"http://purl.obolibrary.org/obo/CHEBI_52999"},{"id":"A185","pred":"chebi_id","subj":"T185","obj":"http://purl.obolibrary.org/obo/CHEBI_10545"},{"id":"A186","pred":"chebi_id","subj":"T186","obj":"http://purl.obolibrary.org/obo/CHEBI_145994"},{"id":"A187","pred":"chebi_id","subj":"T187","obj":"http://purl.obolibrary.org/obo/CHEBI_145924"},{"id":"A188","pred":"chebi_id","subj":"T188","obj":"http://purl.obolibrary.org/obo/CHEBI_31781"},{"id":"A189","pred":"chebi_id","subj":"T189","obj":"http://purl.obolibrary.org/obo/CHEBI_45409"},{"id":"A190","pred":"chebi_id","subj":"T190","obj":"http://purl.obolibrary.org/obo/CHEBI_134730"},{"id":"A191","pred":"chebi_id","subj":"T191","obj":"http://purl.obolibrary.org/obo/CHEBI_3638"},{"id":"A192","pred":"chebi_id","subj":"T192","obj":"http://purl.obolibrary.org/obo/CHEBI_5801"},{"id":"A193","pred":"chebi_id","subj":"T193","obj":"http://purl.obolibrary.org/obo/CHEBI_7798"},{"id":"A194","pred":"chebi_id","subj":"T194","obj":"http://purl.obolibrary.org/obo/CHEBI_2955"},{"id":"A195","pred":"chebi_id","subj":"T195","obj":"http://purl.obolibrary.org/obo/CHEBI_145924"},{"id":"A196","pred":"chebi_id","subj":"T196","obj":"http://purl.obolibrary.org/obo/CHEBI_31781"},{"id":"A197","pred":"chebi_id","subj":"T197","obj":"http://purl.obolibrary.org/obo/CHEBI_45409"},{"id":"A198","pred":"chebi_id","subj":"T198","obj":"http://purl.obolibrary.org/obo/CHEBI_134730"},{"id":"A199","pred":"chebi_id","subj":"T199","obj":"http://purl.obolibrary.org/obo/CHEBI_3638"},{"id":"A200","pred":"chebi_id","subj":"T200","obj":"http://purl.obolibrary.org/obo/CHEBI_5801"},{"id":"A201","pred":"chebi_id","subj":"T201","obj":"http://purl.obolibrary.org/obo/CHEBI_7798"},{"id":"A202","pred":"chebi_id","subj":"T202","obj":"http://purl.obolibrary.org/obo/CHEBI_2955"},{"id":"A203","pred":"chebi_id","subj":"T203","obj":"http://purl.obolibrary.org/obo/CHEBI_23359"},{"id":"A204","pred":"chebi_id","subj":"T204","obj":"http://purl.obolibrary.org/obo/CHEBI_145924"},{"id":"A205","pred":"chebi_id","subj":"T205","obj":"http://purl.obolibrary.org/obo/CHEBI_31781"},{"id":"A206","pred":"chebi_id","subj":"T206","obj":"http://purl.obolibrary.org/obo/CHEBI_45409"},{"id":"A207","pred":"chebi_id","subj":"T207","obj":"http://purl.obolibrary.org/obo/CHEBI_35209"},{"id":"A208","pred":"chebi_id","subj":"T208","obj":"http://purl.obolibrary.org/obo/CHEBI_7798"},{"id":"A209","pred":"chebi_id","subj":"T209","obj":"http://purl.obolibrary.org/obo/CHEBI_3638"},{"id":"A210","pred":"chebi_id","subj":"T210","obj":"http://purl.obolibrary.org/obo/CHEBI_7798"},{"id":"A211","pred":"chebi_id","subj":"T211","obj":"http://purl.obolibrary.org/obo/CHEBI_145924"},{"id":"A212","pred":"chebi_id","subj":"T212","obj":"http://purl.obolibrary.org/obo/CHEBI_31781"},{"id":"A213","pred":"chebi_id","subj":"T213","obj":"http://purl.obolibrary.org/obo/CHEBI_45409"},{"id":"A214","pred":"chebi_id","subj":"T214","obj":"http://purl.obolibrary.org/obo/CHEBI_145924"},{"id":"A215","pred":"chebi_id","subj":"T215","obj":"http://purl.obolibrary.org/obo/CHEBI_31781"},{"id":"A216","pred":"chebi_id","subj":"T216","obj":"http://purl.obolibrary.org/obo/CHEBI_45409"},{"id":"A217","pred":"chebi_id","subj":"T217","obj":"http://purl.obolibrary.org/obo/CHEBI_7798"},{"id":"A218","pred":"chebi_id","subj":"T218","obj":"http://purl.obolibrary.org/obo/CHEBI_367163"},{"id":"A219","pred":"chebi_id","subj":"T219","obj":"http://purl.obolibrary.org/obo/CHEBI_45409"},{"id":"A220","pred":"chebi_id","subj":"T220","obj":"http://purl.obolibrary.org/obo/CHEBI_7798"},{"id":"A221","pred":"chebi_id","subj":"T221","obj":"http://purl.obolibrary.org/obo/CHEBI_134722"},{"id":"A222","pred":"chebi_id","subj":"T222","obj":"http://purl.obolibrary.org/obo/CHEBI_145924"},{"id":"A223","pred":"chebi_id","subj":"T223","obj":"http://purl.obolibrary.org/obo/CHEBI_31781"},{"id":"A224","pred":"chebi_id","subj":"T224","obj":"http://purl.obolibrary.org/obo/CHEBI_45409"},{"id":"A225","pred":"chebi_id","subj":"T225","obj":"http://purl.obolibrary.org/obo/CHEBI_367163"},{"id":"A226","pred":"chebi_id","subj":"T226","obj":"http://purl.obolibrary.org/obo/CHEBI_45409"},{"id":"A227","pred":"chebi_id","subj":"T227","obj":"http://purl.obolibrary.org/obo/CHEBI_7798"},{"id":"A228","pred":"chebi_id","subj":"T228","obj":"http://purl.obolibrary.org/obo/CHEBI_3638"},{"id":"A229","pred":"chebi_id","subj":"T229","obj":"http://purl.obolibrary.org/obo/CHEBI_367163"},{"id":"A230","pred":"chebi_id","subj":"T230","obj":"http://purl.obolibrary.org/obo/CHEBI_45409"},{"id":"A231","pred":"chebi_id","subj":"T231","obj":"http://purl.obolibrary.org/obo/CHEBI_134722"},{"id":"A232","pred":"chebi_id","subj":"T232","obj":"http://purl.obolibrary.org/obo/CHEBI_7798"},{"id":"A233","pred":"chebi_id","subj":"T233","obj":"http://purl.obolibrary.org/obo/CHEBI_35209"}],"text":"• Comparison of lopinavir/ritonavir vs. hydroxychloroquine in patients with mild COVID-19. Open-label RCT (NCT04307693, recruiting). Primary endpoint: virus load at day 3, 5, 7, 10, 14 and 18.\n• Comparison of ASC09/ritonavir vs. lopinavir/ritonavir in patients with confirmed COVID-19 pneumoniae. Open-label RCT (NCT04261907, not yet recruiting). Primary endpoint: adverse outcome at day 14 (composite of Spo 2 ≤ 93% without oxygen supplementation, PaO2/FiO2 ≤ 300 mm Hg or respiratory rate ≥ 30 breaths per minute).\n• Comparison of lopinavir/ritonavir vs. lopinavir/ritonavir plus umifenovir in patients with COVID-19. Open-label RCT (NCT04252885, recruiting). Primary endpoint: rate of virus inhibition at day 0, 2, 4, 7, 10, 14 and 21.\n• Comparison of lopinavir/ritonavir vs. lopinavir/ritonavir plus ribavirin plus interferon beta 1b in patients with COVID-19. Open-label RCT (NCT04276688, recruiting). Primary endpoint: time to negative nasopharyngeal swab RT-PCR (follow-up 30 days).\n• Comparison of only supportive treatment vs. lopinavir/ritonavir vs. oseltamivir vs. umifenovir in patients with confirmed COVID-19 pneumonia. Open-label RCT (NCT04255017, recruiting). Primary endpoints: (a) rate of disease remission (mild disease: fever, cough and other symptoms relieved with improved lung CT; severe disease: fever, cough and other symptoms relieved with improved lung CT, Spo 2 \u003e 93% or Pao 2/Fio 2 \u003e 300 mm Hg); (b) time to lung recovery.\n• Comparison of chemoprophylaxis with lopinavir/ritonavir vs. placebo in healthcare workers exposed to COVID-19. Double-blind RCT (NCT04328285, not yet recruiting). Primary endpoint: occurrence of a symptomatic or asymptomatic COVID-19 (follow-up 2.5 months).\n• Comparison of carrimycin vs. lopinavir/ritonavir or umifenovir or chloroquine in patients with COVID-19 pneumonia. Open-label RCT (NCT04286503, not yet recruiting). Primary endpoints: (a) fever to normal time (follow-up 30 days); (b) pulmonary inflammation resolution time (follow-up 30 days); (c) negative conversion of throat swab RT-PCR at EOT.\n• Comparison of lopinavir/ritonavir vs. lopinavir/ritonavir plus xiyanping (injectable component derived from a plant used in traditional Chinese medicine) in patients with COVID-19. Open-label RCT (NCT04295551, not yet recruiting). Primary endpoint: clinical recovery time (follow-up 28 days).\n• Comparison of lopinavir/ritonavir plus inhaled interferon alfa vs. lopinavir/ritonavir plus inhaled interferon alfa plus xiyanping injection in patients with COVID-19. Open-label RCT (NCT04275388, not yet recruiting). Primary endpoint: clinical recovery time (follow-up 14 days).\n• Comparison of lopinavir/ritonavir plus inhaled interferon alfa vs. lopinavir/ritonavir plus inhaled interferon alfa plus traditional Chinese medicines in patients with COVID-19. Open-label RCT (NCT04251871, recruiting). Primary endpoint: time to complete remission of symptoms (follow-up 28 days).\n• Comparison of lopinavir/ritonavir plus hydroxychloroquine vs. lopinavir/ritonavir plus hydroxychloroquine plus levamisole pill plus budesonide plus formoterol inhaler in patients with nonsevere COVID-19 pneumonia. Partly blinded RCT (NCT04331470, not yet recruiting). Primary endpoint: (a) clear CT scan at 3–7 days; (b) negative RT-PCR at 3–7 days.\n• Comparison of lopinavir/ritonavir vs. hydroxychloroquine vs. losartan vs. placebos in patients with COVID-19. Double-blind, adaptive RCT (NCT04328012, not yet recruiting). Primary endpoint: NIAID COVID-19 ordinal severity scale (follow-up 60 days).\n• Comparison of lopinavir/ritonavir vs. hydroxychloroquine vs. lopinavir/ritonavir plus interferon beta 1a vs. remdesivir vs. standard of care in patients with COVID-19. Double-blind, adaptive RCT (NCT04315948, recruiting). Primary endpoint: severity rating on a 7-point ordinal scale at day 15.\n• Comparison of lopinavir/ritonavir or umifenovir or chloroquine or hydroxychloroquine or oseltamivir (with or without azithromycin) vs. natural honey plus lopinavir/ritonavir or umifenovir or chloroquine or hydroxychloroquine or oseltamivir (with or without azithromycin) in patients with COVID-19. Single-blind RCT (NCT04323345, not yet recruiting). Primary endpoints: (a) positive to negative swabs at day 14; (b) fever to normal temperature in days (follow-up 14 days); (c) resolution of lung inflammation in CT or X-ray (follow-up 30 days).\n• Comparison of colchicine (with or without lopinavir/ritonavir) vs. local standard of care in patients with moderate to severe COVID-19. Open-label RCT (NCT04328480, not yet recruiting). Primary endpoint: all-cause mortality (follow-up 30 days).\n• Comparison of oseltamivir plus chloroquine vs. oseltamivir plus lopinavir/ritonavir in patients with mild COVID-19 and of lopinavir/ritonavir plus oseltamivir vs. darunavir/ritonavir plus oseltamivir vs. favipiravir plus lopinavir/ritonavir vs. darunavir/ritonavir plus oseltamivir plus chloroquine vs. darunavir/ritonavir plus favipiravir plus oseltamivir in patients with moderate to severe COVID-19. Open-label RCT (NCT04303299, not yet recruiting). Primary endpoint: SARS-CoV-2 eradication time (follow-up 24 weeks)."}
LitCovid-PD-GO-BP
{"project":"LitCovid-PD-GO-BP","denotations":[{"id":"T3","span":{"begin":1958,"end":1970},"obj":"http://purl.obolibrary.org/obo/GO_0006954"},{"id":"T4","span":{"begin":4335,"end":4347},"obj":"http://purl.obolibrary.org/obo/GO_0006954"}],"text":"• Comparison of lopinavir/ritonavir vs. hydroxychloroquine in patients with mild COVID-19. Open-label RCT (NCT04307693, recruiting). Primary endpoint: virus load at day 3, 5, 7, 10, 14 and 18.\n• Comparison of ASC09/ritonavir vs. lopinavir/ritonavir in patients with confirmed COVID-19 pneumoniae. Open-label RCT (NCT04261907, not yet recruiting). Primary endpoint: adverse outcome at day 14 (composite of Spo 2 ≤ 93% without oxygen supplementation, PaO2/FiO2 ≤ 300 mm Hg or respiratory rate ≥ 30 breaths per minute).\n• Comparison of lopinavir/ritonavir vs. lopinavir/ritonavir plus umifenovir in patients with COVID-19. Open-label RCT (NCT04252885, recruiting). Primary endpoint: rate of virus inhibition at day 0, 2, 4, 7, 10, 14 and 21.\n• Comparison of lopinavir/ritonavir vs. lopinavir/ritonavir plus ribavirin plus interferon beta 1b in patients with COVID-19. Open-label RCT (NCT04276688, recruiting). Primary endpoint: time to negative nasopharyngeal swab RT-PCR (follow-up 30 days).\n• Comparison of only supportive treatment vs. lopinavir/ritonavir vs. oseltamivir vs. umifenovir in patients with confirmed COVID-19 pneumonia. Open-label RCT (NCT04255017, recruiting). Primary endpoints: (a) rate of disease remission (mild disease: fever, cough and other symptoms relieved with improved lung CT; severe disease: fever, cough and other symptoms relieved with improved lung CT, Spo 2 \u003e 93% or Pao 2/Fio 2 \u003e 300 mm Hg); (b) time to lung recovery.\n• Comparison of chemoprophylaxis with lopinavir/ritonavir vs. placebo in healthcare workers exposed to COVID-19. Double-blind RCT (NCT04328285, not yet recruiting). Primary endpoint: occurrence of a symptomatic or asymptomatic COVID-19 (follow-up 2.5 months).\n• Comparison of carrimycin vs. lopinavir/ritonavir or umifenovir or chloroquine in patients with COVID-19 pneumonia. Open-label RCT (NCT04286503, not yet recruiting). Primary endpoints: (a) fever to normal time (follow-up 30 days); (b) pulmonary inflammation resolution time (follow-up 30 days); (c) negative conversion of throat swab RT-PCR at EOT.\n• Comparison of lopinavir/ritonavir vs. lopinavir/ritonavir plus xiyanping (injectable component derived from a plant used in traditional Chinese medicine) in patients with COVID-19. Open-label RCT (NCT04295551, not yet recruiting). Primary endpoint: clinical recovery time (follow-up 28 days).\n• Comparison of lopinavir/ritonavir plus inhaled interferon alfa vs. lopinavir/ritonavir plus inhaled interferon alfa plus xiyanping injection in patients with COVID-19. Open-label RCT (NCT04275388, not yet recruiting). Primary endpoint: clinical recovery time (follow-up 14 days).\n• Comparison of lopinavir/ritonavir plus inhaled interferon alfa vs. lopinavir/ritonavir plus inhaled interferon alfa plus traditional Chinese medicines in patients with COVID-19. Open-label RCT (NCT04251871, recruiting). Primary endpoint: time to complete remission of symptoms (follow-up 28 days).\n• Comparison of lopinavir/ritonavir plus hydroxychloroquine vs. lopinavir/ritonavir plus hydroxychloroquine plus levamisole pill plus budesonide plus formoterol inhaler in patients with nonsevere COVID-19 pneumonia. Partly blinded RCT (NCT04331470, not yet recruiting). Primary endpoint: (a) clear CT scan at 3–7 days; (b) negative RT-PCR at 3–7 days.\n• Comparison of lopinavir/ritonavir vs. hydroxychloroquine vs. losartan vs. placebos in patients with COVID-19. Double-blind, adaptive RCT (NCT04328012, not yet recruiting). Primary endpoint: NIAID COVID-19 ordinal severity scale (follow-up 60 days).\n• Comparison of lopinavir/ritonavir vs. hydroxychloroquine vs. lopinavir/ritonavir plus interferon beta 1a vs. remdesivir vs. standard of care in patients with COVID-19. Double-blind, adaptive RCT (NCT04315948, recruiting). Primary endpoint: severity rating on a 7-point ordinal scale at day 15.\n• Comparison of lopinavir/ritonavir or umifenovir or chloroquine or hydroxychloroquine or oseltamivir (with or without azithromycin) vs. natural honey plus lopinavir/ritonavir or umifenovir or chloroquine or hydroxychloroquine or oseltamivir (with or without azithromycin) in patients with COVID-19. Single-blind RCT (NCT04323345, not yet recruiting). Primary endpoints: (a) positive to negative swabs at day 14; (b) fever to normal temperature in days (follow-up 14 days); (c) resolution of lung inflammation in CT or X-ray (follow-up 30 days).\n• Comparison of colchicine (with or without lopinavir/ritonavir) vs. local standard of care in patients with moderate to severe COVID-19. Open-label RCT (NCT04328480, not yet recruiting). Primary endpoint: all-cause mortality (follow-up 30 days).\n• Comparison of oseltamivir plus chloroquine vs. oseltamivir plus lopinavir/ritonavir in patients with mild COVID-19 and of lopinavir/ritonavir plus oseltamivir vs. darunavir/ritonavir plus oseltamivir vs. favipiravir plus lopinavir/ritonavir vs. darunavir/ritonavir plus oseltamivir plus chloroquine vs. darunavir/ritonavir plus favipiravir plus oseltamivir in patients with moderate to severe COVID-19. Open-label RCT (NCT04303299, not yet recruiting). Primary endpoint: SARS-CoV-2 eradication time (follow-up 24 weeks)."}
LitCovid-sentences
{"project":"LitCovid-sentences","denotations":[{"id":"T97","span":{"begin":91,"end":132},"obj":"Sentence"},{"id":"T98","span":{"begin":133,"end":192},"obj":"Sentence"},{"id":"T99","span":{"begin":193,"end":296},"obj":"Sentence"},{"id":"T100","span":{"begin":297,"end":346},"obj":"Sentence"},{"id":"T101","span":{"begin":347,"end":516},"obj":"Sentence"},{"id":"T102","span":{"begin":517,"end":619},"obj":"Sentence"},{"id":"T103","span":{"begin":620,"end":661},"obj":"Sentence"},{"id":"T104","span":{"begin":662,"end":738},"obj":"Sentence"},{"id":"T105","span":{"begin":739,"end":864},"obj":"Sentence"},{"id":"T106","span":{"begin":865,"end":906},"obj":"Sentence"},{"id":"T107","span":{"begin":907,"end":989},"obj":"Sentence"},{"id":"T108","span":{"begin":990,"end":1133},"obj":"Sentence"},{"id":"T109","span":{"begin":1134,"end":1175},"obj":"Sentence"},{"id":"T110","span":{"begin":1176,"end":1451},"obj":"Sentence"},{"id":"T111","span":{"begin":1452,"end":1564},"obj":"Sentence"},{"id":"T112","span":{"begin":1565,"end":1616},"obj":"Sentence"},{"id":"T113","span":{"begin":1617,"end":1711},"obj":"Sentence"},{"id":"T114","span":{"begin":1712,"end":1828},"obj":"Sentence"},{"id":"T115","span":{"begin":1829,"end":1878},"obj":"Sentence"},{"id":"T116","span":{"begin":1879,"end":2061},"obj":"Sentence"},{"id":"T117","span":{"begin":2062,"end":2244},"obj":"Sentence"},{"id":"T118","span":{"begin":2245,"end":2294},"obj":"Sentence"},{"id":"T119","span":{"begin":2295,"end":2356},"obj":"Sentence"},{"id":"T120","span":{"begin":2357,"end":2526},"obj":"Sentence"},{"id":"T121","span":{"begin":2527,"end":2576},"obj":"Sentence"},{"id":"T122","span":{"begin":2577,"end":2638},"obj":"Sentence"},{"id":"T123","span":{"begin":2639,"end":2818},"obj":"Sentence"},{"id":"T124","span":{"begin":2819,"end":2860},"obj":"Sentence"},{"id":"T125","span":{"begin":2861,"end":2938},"obj":"Sentence"},{"id":"T126","span":{"begin":2939,"end":3154},"obj":"Sentence"},{"id":"T127","span":{"begin":3155,"end":3208},"obj":"Sentence"},{"id":"T128","span":{"begin":3209,"end":3290},"obj":"Sentence"},{"id":"T129","span":{"begin":3291,"end":3402},"obj":"Sentence"},{"id":"T130","span":{"begin":3403,"end":3464},"obj":"Sentence"},{"id":"T131","span":{"begin":3465,"end":3541},"obj":"Sentence"},{"id":"T132","span":{"begin":3542,"end":3711},"obj":"Sentence"},{"id":"T133","span":{"begin":3712,"end":3765},"obj":"Sentence"},{"id":"T134","span":{"begin":3766,"end":3837},"obj":"Sentence"},{"id":"T135","span":{"begin":3838,"end":4137},"obj":"Sentence"},{"id":"T136","span":{"begin":4138,"end":4189},"obj":"Sentence"},{"id":"T137","span":{"begin":4190,"end":4383},"obj":"Sentence"},{"id":"T138","span":{"begin":4384,"end":4521},"obj":"Sentence"},{"id":"T139","span":{"begin":4522,"end":4571},"obj":"Sentence"},{"id":"T140","span":{"begin":4572,"end":4630},"obj":"Sentence"},{"id":"T141","span":{"begin":4631,"end":5035},"obj":"Sentence"},{"id":"T142","span":{"begin":5036,"end":5085},"obj":"Sentence"},{"id":"T143","span":{"begin":5086,"end":5153},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"• Comparison of lopinavir/ritonavir vs. hydroxychloroquine in patients with mild COVID-19. Open-label RCT (NCT04307693, recruiting). Primary endpoint: virus load at day 3, 5, 7, 10, 14 and 18.\n• Comparison of ASC09/ritonavir vs. lopinavir/ritonavir in patients with confirmed COVID-19 pneumoniae. Open-label RCT (NCT04261907, not yet recruiting). Primary endpoint: adverse outcome at day 14 (composite of Spo 2 ≤ 93% without oxygen supplementation, PaO2/FiO2 ≤ 300 mm Hg or respiratory rate ≥ 30 breaths per minute).\n• Comparison of lopinavir/ritonavir vs. lopinavir/ritonavir plus umifenovir in patients with COVID-19. Open-label RCT (NCT04252885, recruiting). Primary endpoint: rate of virus inhibition at day 0, 2, 4, 7, 10, 14 and 21.\n• Comparison of lopinavir/ritonavir vs. lopinavir/ritonavir plus ribavirin plus interferon beta 1b in patients with COVID-19. Open-label RCT (NCT04276688, recruiting). Primary endpoint: time to negative nasopharyngeal swab RT-PCR (follow-up 30 days).\n• Comparison of only supportive treatment vs. lopinavir/ritonavir vs. oseltamivir vs. umifenovir in patients with confirmed COVID-19 pneumonia. Open-label RCT (NCT04255017, recruiting). Primary endpoints: (a) rate of disease remission (mild disease: fever, cough and other symptoms relieved with improved lung CT; severe disease: fever, cough and other symptoms relieved with improved lung CT, Spo 2 \u003e 93% or Pao 2/Fio 2 \u003e 300 mm Hg); (b) time to lung recovery.\n• Comparison of chemoprophylaxis with lopinavir/ritonavir vs. placebo in healthcare workers exposed to COVID-19. Double-blind RCT (NCT04328285, not yet recruiting). Primary endpoint: occurrence of a symptomatic or asymptomatic COVID-19 (follow-up 2.5 months).\n• Comparison of carrimycin vs. lopinavir/ritonavir or umifenovir or chloroquine in patients with COVID-19 pneumonia. Open-label RCT (NCT04286503, not yet recruiting). Primary endpoints: (a) fever to normal time (follow-up 30 days); (b) pulmonary inflammation resolution time (follow-up 30 days); (c) negative conversion of throat swab RT-PCR at EOT.\n• Comparison of lopinavir/ritonavir vs. lopinavir/ritonavir plus xiyanping (injectable component derived from a plant used in traditional Chinese medicine) in patients with COVID-19. Open-label RCT (NCT04295551, not yet recruiting). Primary endpoint: clinical recovery time (follow-up 28 days).\n• Comparison of lopinavir/ritonavir plus inhaled interferon alfa vs. lopinavir/ritonavir plus inhaled interferon alfa plus xiyanping injection in patients with COVID-19. Open-label RCT (NCT04275388, not yet recruiting). Primary endpoint: clinical recovery time (follow-up 14 days).\n• Comparison of lopinavir/ritonavir plus inhaled interferon alfa vs. lopinavir/ritonavir plus inhaled interferon alfa plus traditional Chinese medicines in patients with COVID-19. Open-label RCT (NCT04251871, recruiting). Primary endpoint: time to complete remission of symptoms (follow-up 28 days).\n• Comparison of lopinavir/ritonavir plus hydroxychloroquine vs. lopinavir/ritonavir plus hydroxychloroquine plus levamisole pill plus budesonide plus formoterol inhaler in patients with nonsevere COVID-19 pneumonia. Partly blinded RCT (NCT04331470, not yet recruiting). Primary endpoint: (a) clear CT scan at 3–7 days; (b) negative RT-PCR at 3–7 days.\n• Comparison of lopinavir/ritonavir vs. hydroxychloroquine vs. losartan vs. placebos in patients with COVID-19. Double-blind, adaptive RCT (NCT04328012, not yet recruiting). Primary endpoint: NIAID COVID-19 ordinal severity scale (follow-up 60 days).\n• Comparison of lopinavir/ritonavir vs. hydroxychloroquine vs. lopinavir/ritonavir plus interferon beta 1a vs. remdesivir vs. standard of care in patients with COVID-19. Double-blind, adaptive RCT (NCT04315948, recruiting). Primary endpoint: severity rating on a 7-point ordinal scale at day 15.\n• Comparison of lopinavir/ritonavir or umifenovir or chloroquine or hydroxychloroquine or oseltamivir (with or without azithromycin) vs. natural honey plus lopinavir/ritonavir or umifenovir or chloroquine or hydroxychloroquine or oseltamivir (with or without azithromycin) in patients with COVID-19. Single-blind RCT (NCT04323345, not yet recruiting). Primary endpoints: (a) positive to negative swabs at day 14; (b) fever to normal temperature in days (follow-up 14 days); (c) resolution of lung inflammation in CT or X-ray (follow-up 30 days).\n• Comparison of colchicine (with or without lopinavir/ritonavir) vs. local standard of care in patients with moderate to severe COVID-19. Open-label RCT (NCT04328480, not yet recruiting). Primary endpoint: all-cause mortality (follow-up 30 days).\n• Comparison of oseltamivir plus chloroquine vs. oseltamivir plus lopinavir/ritonavir in patients with mild COVID-19 and of lopinavir/ritonavir plus oseltamivir vs. darunavir/ritonavir plus oseltamivir vs. favipiravir plus lopinavir/ritonavir vs. darunavir/ritonavir plus oseltamivir plus chloroquine vs. darunavir/ritonavir plus favipiravir plus oseltamivir in patients with moderate to severe COVID-19. Open-label RCT (NCT04303299, not yet recruiting). Primary endpoint: SARS-CoV-2 eradication time (follow-up 24 weeks)."}